<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1904221963
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EPIZOLONE DEPOT 40MG/ML VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METHYLPREDNISOLONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        10.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="EIPICO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            EIPICO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 449]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Khalid Bin Saad Int. Company LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            EIPICO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H02AB04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Epizolone-Depot contains Methylprednisolone Acetate.</p><p>Methylprednisolone belongs to a group of medicines called corticosteroids or steroids.</p><p>Corticosteroids are produced naturally in your body and are important for many body functions.</p><p>Boosting your body with extra corticosteroid such as Epizolone-Depot can help when injected into the body by a doctor or nurse, such as in or near a joint, to treat local symptoms caused by inflammatory or rheumatic conditions such as:</p><p>- Bursitis: inflammation in the fluid containing spaces around the shoulder, knee and/or elbow joints. For this condition this medicine will be injected directly into one or more of these spaces.</p><p>- Osteoarthritis and rheumatoid arthritis: inflammation located in between the joints. For these conditions this medicine will be injected directly into one or more joint spaces.</p><p>- Plantar fasciitis: inflammation of the tissues of the sole of the foot.</p><p>- Skin problems: such as alopecia areata (patchy baldness), keloids (scar tissue), lichen planus or simplex (small, purplish raised patches of skin or spots), discoid lupus (round-shaped patches, often on the face) or granuloma annulare (circular warty growths).</p><p>- Epicondylitis (tennis elbow) and tenosynovitis: For these conditions this medicine will be injected into the tendon sheath.</p><p>Alternatively this medicine may be injected into a muscle to help treat more general (systemic) problems affecting the whole body (e.g. symptoms caused by a hypersensitivity to a medicine), or allergic, inflammatory or rheumatic problems affecting the:</p><p>- Brain e.g. meningitis caused by tuberculosis</p><p>- Bowel and gut e.g. Crohn&rsquo;s disease (inflammation of the gut) or ulcerative colitis (inflammation of the lower bowel)</p><p>- Joints e.g. rheumatoid arthritis</p><p>- Lungs e.g. asthma, severe hay fever or rhinitis, tuberculosis or inflammation caused by breathing in (aspirating) vomit or stomach contents</p><p>- skin e.g. Stevens-Johnson syndrome (an &lsquo;auto-immune disorder in which an immune system causes the skin to blister and peel) or systemic lupus erythematosus (lupus),</p><p>Your doctor may use this medicine to treat conditions other than those listed above.</p><p>Ask your doctor if you are unsure why you have been given this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Epizolone-Depot if:</p><p>- You think you have ever suffered an allergic reaction, or any other type of reaction after being given Epizolone-Depot , or any other medicine containing a corticosteroid or any of the ingredients in this medicine (Section 6 of this leaflet contains a list of ingredients).An allergic reaction may cause a skin rash or reddening, swollen face or lips or shortness of breath.</p><p>- You get a rash, or another symptom of an infection.</p><p>See your doctor immediately if you have any of the above.</p><p>&nbsp;</p><p>Do not inject this medicine into:</p><p>- The Achilles tendon (which is located behind the ankle joint), or</p><p>- Directly into a vein (intravenous), the spinal cord (intrathecal), the outer covering of the brain (extradural), into the nostrils (intranasal) or in the eye (intraocular).</p><p>Take special care before taking Epizolone-Depot:</p><p>You must tell your doctor before you take this medicine if you have any of the following conditions.</p><p>Your doctor may also have to monitor your treatment more closely, alter your dose or give you another medicine.</p><p>- Acute adrenal insufficiency (when your body cannot produce enough corticosteroid due to problems with your adrenal glands).</p><p>- Acute pancreatitis (inflammation of the pancreas).</p><p>- Chickenpox, shingles or a herpes eye infection. If you think you have been in contact with someone with chickenpox or shingles and you have not already had these illnesses, or if you are unsure if you have had them.</p><p>- Severe depression or manic depression (bipolar disorder). This includes having had depression before while taking steroid medicines like Epizolone-Depot , or having a family history of these illnesses.</p><p>- Diabetes (or if there is a family history of diabetes).</p><p>- Epilepsy.</p><p>- Glaucoma (increased pressure in the eye) or if there is a family history of glaucoma.</p><p>- You have recently suffered a heart attack.</p><p>- Heart problems, including heart failure or infections.</p><p>- Hypertension (high blood pressure).</p><p>- Hypothyroidism (an under-active thyroid).</p><p>- Joint infection</p><p>- Kidney or liver disease.</p><p>- Muscle problems (pain or weakness) have happened while taking steroid medicines in the past.</p><p>- Myasthenia gravis (a condition causing tired and weak muscles).</p><p>- Osteoporosis (brittle bones).</p><p>- Skin abscess.</p><p>- Stomach ulcer or other serious stomach or intestinal problems.</p><p>- Thrombophlebitis - vein problems due to thrombosis (clots in the veins) resulting in phlebitis (red, swollen and tender veins).</p><p>- Tuberculosis (TB) or if you have suffered tuberculosis in the past.</p><p>You must tell your doctor before you take this medicine if you have any of the conditions listed above.</p><p>Taking other medicines</p><p>Always tell your doctor or pharmacist if you are taking any medicines (including any you have bought without a prescription) as taking Epizolone-Depot with other medicines could be harmful.</p><p>You should tell your doctor if you are taking any of the following medicines which can affect the way Epizolone-Depot or the other medicine works:</p><p>- Acetazolamide - used to treat glaucoma and epilepsy</p><p>- Aminoglutethimide &ndash; used for treating cancer</p><p>- Antibacterials (such as isoniazid, erythromycin, clarithromycin and troleandomycin).</p><p>- Anticoagulants - used to &lsquo;thin&rsquo; the blood such as acenocoumarol,phenindione and warfarin</p><p>- Anticholinesterases - used to treat myasthenia gravis (a muscle condition) such as distigmine and neostigmine</p><p>- Antidiabetics &ndash; medicines used to treat high blood sugar.</p><p>- Antiemetics (such as aprepitant and fosaprepitant).</p><p>- Aspirin and non-steroidal anti-inflammatory medicines (also called NSAIDs) such as ibuprofen used to treat mild to moderate pain</p><p>- Barbiturates, carbamazepine, phenytoin and primidone &ndash; used to treat epilepsy</p><p>- Carbenoxolone - used for heartburn and acid indigestion</p><p>- Ciclosporin - used to treat conditions such as severe rheumatoid arthritis,severe psoriasis or following an organ or bone marrow transplant</p><p>- Digoxin - used for heart failure and/or an irregular heart beat</p><p>- Diltiazem or mibefradil &ndash; used for heart problems or high blood pressure</p><p>- Ethinylestradiol and norethindrone (oral contraceptives).</p><p>- Indinavir and ritonavir used to treat HIV infections.</p><p>- Ketoconazole or itraconazole &ndash; used to treat fungal infections</p><p>- Pancuronium &ndash; or other medicines called neuromuscular blocking agents which are used in some surgical procedures</p><p>- Potassium depleting agents &ndash; such as diuretics (sometimes called water tablets), amphotericin B, xanthenes or beta2 agonists (e.g. medicines used to treat asthma).</p><p>- Rifampicin and rifabutin &ndash; antibiotics used to treat tuberculosis (TB)</p><p>- Tacrolimus &ndash; used following an organ transplant to prevent rejection of the organ.</p><p>- Vaccines - tell your doctor or nurse if you have recently had, or are about to have any vaccination. You should not have &lsquo;live&rsquo; vaccines while using this medicine. Other vaccines may be less effective</p><p>If you are taking long term medication(s)</p><p>If you are being treated for diabetes, high blood pressure or water retention (oedema) tell your doctor as he/she may need to adjust the dose of the medicines used to treat these conditions.</p><p>Before you have any operation tell your doctor, dentist or anesthetist that you are taking this medicine.</p><p>If you require a test to be carried out by your doctor or in hospital it is important that you tell the doctor or nurse that you are taking Epizolone-Depot . This medicine can affect the results of some tests.</p><p>Epizolone-Depot&nbsp; with drink</p><p>Do not drink grapefruit juice while taking this medicine.</p><p>Pregnancy and breast feeding</p><p>You must tell your doctor if you are pregnant, think you might be pregnant or are trying to become pregnant as this medicine could slow the baby&rsquo;s growth.</p><p>Cataracts have been observed in infants born to mothers treated with long-term corticosteroids during pregnancy.</p><p>Tell your doctor if you are breast feeding as small amounts of corticosteroid medicines may get into breast milk.</p><p>If you continue breast-feeding while you are having treatment, your baby will need extra checks to make sure he or she is not being affected by your medicine.</p><p>Driving and Using Machines</p><p>There are no special precautions while you are being treated with this medicine.</p><p>Epizolone-Depot contains sodium</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dosage information</p><p>Your doctor will decide on the site of injection, how much of the medicine and how many injections you will receive depending on the condition being treated and its severity. Your doctor will inject you with the lowest dose for the shortest possible time to get effective relief of your symptoms.</p><p>Adults</p><p>Your doctor/nurse will tell you how many injections you will require for the condition you are being treated for, and when you will get them.</p><p>Joints - the normal dose for the injections into joint will depend on the size of the joint. Large joints (e.g. knee, ankle and shoulder) may require 20 - 80 mg (0.5 &ndash; 2 ml), medium sized joints (e.g. elbow or wrist) 10 - 40 mg (0.25 &ndash; 1 ml) and small joints</p><p>(e.g. finger or toe joints) may require a 4 - 10 mg (0.1 -0.25 ml) dose.</p><p>Joint injections may be given weekly over a period of several weeks, depending on how quickly you respond to treatment.</p><p>Bursitis and epicondylitis (tennis elbow) &ndash; the usual dose is between 4-30 mg (0.1 -</p><p>0.75 ml). In most cases repeat injections will not needed for bursitis and epicondylitis.Repeat injections may be necessary to treat long standing conditions.</p><p>Skin conditions &ndash; the usual dose is between 20 &ndash; 60mg (0.5 &ndash; 1.5ml) injected into the affected part or parts of the skin.</p><p>For other more general conditions 40 &ndash; 120 mg (1 &ndash; 3ml) of this medicine may be injected into a large muscle.</p><p>Elderly</p><p>Treatment will normally be the same as for younger adults. However your doctor may want to see you more regularly to check how you are getting on with this medicine.</p><p>Children</p><p>Corticosteroids can affect growth in children so your doctor will prescribe the lowest dose that will be effective for your child.</p><p>If you are given more Epizolone-Depot than you should</p><p>If you think you have been given too many injections of this medicine please speak to your doctor immediately.</p><p>Stopping/reducing the dose of your Epizolone-Depot</p><p>Your doctor will decide when it is time to stop your treatment.</p><p>You will need to come off this treatment slowly if you:</p><p>- have been given Epizolone-Depot for more than 3 weeks;</p><p>- have been given high doses of Epizolone-Depot , over 32 mg (0.8 ml) daily, even if it was only for 3 weeks or less;</p><p>- have already had a course of corticosteroid tablets or injections in the last year;</p><p>&nbsp;Already have problems with your adrenal glands (adrenocortical insufficiency) before you started this treatment.</p><p>You will need to come off this medicine slowly to avoid withdrawal symptoms.</p><p>These symptoms may include itchy skin, fever, muscle and joint pains, runny nose, sticky eyes, sweating and weight loss.</p><p>If your symptoms seem to return or get worse as your dose of this medicine is reduced tell your doctor immediately.</p><p>Mental problems while taking Epizolone-Depot</p><p>Mental health problems can happen while taking steroids like Epizolone-Depot (see also section 4, Possible Side Effects).</p><p>- These illnesses can be serious.</p><p>- Usually they start within a few days or weeks of starting the medicine.</p><p>- They are more likely to happen at high doses.</p><p>- Most of these problems go away if the dose is lowered or the medicine is stopped. However if the problems do happen they might need treatment.</p><p>Talk to a doctor if you (or someone using this medicine) show any signs of mental problems. This is particularly important if you are depressed, or might be thinking about suicide. In a few cases mental problems have happened when doses are being lowered or stopped.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all steroids this medicine can cause side-effects, although not everybody gets them. Your doctor will have given you this medicine for a condition which if not treated properly could become serious.</p><p>In certain medical conditions medicines like Epizolone-Depot (steroids) should not be stopped abruptly, if you suffer from any of the following symptoms seek</p><p>IMMEDIATE medical attention, you doctor will then decide whether you should continue taking your medicine:</p><p>- Allergic reactions, such as skin rash, swelling of the face or wheezing and-difficulty breathing. This type of side effect is rare, but can be serious.</p><p>- pancreatitis, stomach pain spreading to your back, possibly accompanied by vomiting, shock and loss of consciousness.</p><p>- ulcers or bleeding ulcers, symptoms of which are severe stomach pain which may go through to the back and could be associated with bleeding from the back passage, black or bloodstained stools and/or vomiting blood.</p><p>- Infections. This medicine can hide or change the signs and symptoms of some infections, or reduce your resistance to the infection, so that they are hard to diagnose at an early stage. Symptoms might include a raised temperature and feeling unwell. Symptoms of a flare up of a previous TB infection could be coughing blood or pain in the chest. This medicine may also make you more likely to develop a severe infection.</p><p>- Peritonitis, an inflammation (irritation) of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs. Symptoms are, the stomach (abdomen) being very painful or tender, the pain may become worse when the stomach is touched or when you move.</p><p>- Pulmonary embolus (blood clot in the lung) symptoms include sudden sharp chest pain, breathlessness and coughing up blood.</p><p>- Raised pressure within the skull of children (pseudotumour cerebri) -symptoms of which are headaches with vomiting, lack of energy and drowsiness. This side-effect usually occurs after treatment is stopped.</p><p>- Thrombophlebitis (blood clots or thrombosis in a leg vein), symptoms of which include painful swollen, red and tender veins.</p><p>If you experience any of the following side effects, or notice any other unusual effects not mentioned in this leaflet, tell your doctor immediately:</p><p>The side effects may occur with certain frequencies, which are defined as follows:</p><p> not known: frequency cannot be estimated from the available data</p><p>Blood, heart and circulation</p><p>not known</p><p>- High blood pressure, symptoms of which are headaches, or generally feeling unwell.</p><p>- Problems with the pumping of your heart (heart failure) symptoms of which are swollen ankles, difficulty in breathing and palpitations (awareness of heart beat) or irregular beating of the heart, irregular or very fast or slow pulse.</p><p>- Low blood pressure, symptoms may include dizziness, fainting, lightheadedness, blurred vision, a rapid or irregular heartbeat (palpitations).</p><p>- Increase of white blood cells (leukocytosis).</p><p>- Increased clotting of the blood.</p><p>Body water and salts</p><p>not known</p><p>- Swelling and high blood pressure, caused by increased levels of water and salt content.</p><p>- Cramps and spasms, due to the loss of potassium from your body. In rare cases this can lead to congestive heart failure (when the heart cannot pump properly).</p><p>Digestive system</p><p>not known</p><p>- Ulcers.</p><p>- Nausea (feeling sick) or vomiting (being sick).</p><p>- Thrush in the gullet (discomfort on swallowing).</p><p>- Indigestion.</p><p>- Diarrhoea.</p><p>- Bloated stomach.</p><p>- Abdominal pain.</p><p>- Persistent hiccups, especially when high doses are taken.</p><p>Ears</p><p>not known</p><p>- A feeling of dizziness or spinning (vertigo).</p><p>Eyes</p><p>not known</p><p>- Cataracts (indicated by failing eyesight).</p><p>- Glaucoma(raised pressure within the eye, causing pain in the eyes and headaches).</p><p>- Swollen optic nerve (causing a condition called papilloedema, and which may cause sight disturbance).</p><p>- Increased intra-ocular pressure, with possible damage to the optic nerve (indicated by failing eyesight).</p><p>- Thinning of the clear part at the front of the eye (cornea) or of the white part of the eye (sclera).</p><p>- Worsening of viral or fungal eye infections.</p><p>- Protruding of the eyeballs (exophthalmos).</p><p>- Blurred or distorted vision (due to disease of the retina and choroid membrane).</p><p>General disorders</p><p>not known</p><p>- Poor wound healing.</p><p>- Irritability in children.</p><p>- Feeling tired or unwell.</p><p>- Skin reactions at the site of injection.</p><p>- Irritability in adults.</p><p>Hepatobiliary disorders</p><p>- Methylprednisolone can damage your liver, hepatitis and increase of liver enzymes have been reported.</p><p>Hormones and metabolic system</p><p>not known</p><p>- Slowing of normal growth in infants, children and adolescents which may be permanent.</p><p>- Round or moon-shaped face (Cushingoid facies).</p><p>- Diabetes or worsening of existing diabetes.</p><p>- Irregular or no periods in women.</p><p>- Increased appetite and weight gain.</p><p>- Abnormal localized or tumour-like accumulations of fat in the tissues.</p><p>- Prolonged therapy can lead to lower levels of some hormones which in turn can cause low blood pressure and dizziness. This effect may persist for months.</p><p>- The amount of certain chemicals (enzymes) called alanine transaminase, aspartate transaminase and alkaline phosphatase that help the body digest drugs and other substances in your body may be raised after treatment with a corticosteroid. The change is usually small and the enzyme levels return to normal after your medicine has cleared naturally from your system. You will not notice any symptoms if this happens, but it will show up if you have a blood test.</p><p>Immune system</p><p>not known</p><p>- Increased susceptibility to infections which can hide or change normal reactions to skin tests, such as that for tuberculosis.</p><p>Metabolism and nutrition disorders</p><p>- Accumulation of fat tissue on localized parts of the body.</p><p>Muscles, bones and joints</p><p>not known</p><p>- Muscle weakness .</p><p>- Brittle bones (bones that break easily).</p><p>- Muscle wasting.</p><p>- Broken bones or fractures.</p><p>- Breakdown of bone due to poor circulation of blood, this causes pain in the hip.</p><p>- Joint pain.</p><p>- Torn muscle tendons causing pain and/or swelling.</p><p>- Muscle cramps or spasms.</p><p>- Swollen or painful joints due to infection.</p><p>Nerves and mood issues</p><p>not known</p><p>Steroids including methylprednisolone can cause serious mental health problems.</p><p>These are common in both adults and children. They can affect about 5 in every 100 people taking medicines like methylprednisolone.</p><p>- Feeling depressed, including thinking about suicide.</p><p>- Feeling high (mania) or moods that go up and down.</p><p>- Feeling anxious, having problems sleeping, difficulty in thinking or being confused and losing your memory.</p><p>- Feeling, seeing or hearing things which do not exist. Having strange and frightening thoughts, changing how you act or having feelings of being alone.</p><p>- Other nervous system side effects may include convulsions (seizures), amnesia (loss of memory), cognitive disorder (mental changes, dizziness and headache.</p><p>- Back pain or weakness (due to Epidural Lipomatosis, a rare disorder in which an abnormal amount of fat is deposited on or outside the lining of the spine).</p><p>Skin</p><p>not known</p><p>- Abscess, especially near injection sites</p><p>- Acne.</p><p>- Poor wound healing.</p><p>- Thinning of skin with stretch marks.</p><p>- Bruising.</p><p>- Small purple/red patches on the skin.</p><p>- Pale or darker patches on your skin, or raised patches which are an unusual color.</p><p>- Increased hair on the body and face (hirsutism).</p><p>- Rash, itching, hives.</p><p>- Increased sweating.</p><p>If you experience any of the side effects listed above tell your doctor straight immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- This medicine must not be used after the expiry date &lsquo;EXP&rsquo; shown on the container.</p><p>- This medicine must Store in temperature not exceeding 30&deg;C, but must not be frozen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Active ingredient.</p><p>Each milliliter of this medicine contains 40 mg of methlyprednisolone acetate</p><p>Inactive ingredient</p><p>Sodium chloride, polyethylene glycol, benzethonium chloride, sodium hydroxide, hydrochloric acid, and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Epizolone-Depot: carton box containing 1 vial of 1 or 2 ml. and an inner leaflet.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Egyptian International Pharmaceutical Industries Company, EIPICO</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL" style="text-align:right">إبيزولون - ديبو يحتوي على أسيتات الميثيل بريدنيزولون.</p><p dir="RTL" style="text-align:right">بريدنيزولون ينتمي إلى مجموعة من الأدوية تسمى الكورتيكوستيرويدات أو الاستيرويد.</p><p dir="RTL" style="text-align:right">ويتم إنتاج الكورتيكوستيرويدات بشكل طبيعي في الجسم وهي مهمة بالنسبة للعديد من وظائف الجسم.</p><p dir="RTL" style="text-align:right">تعزيز الجسم بكميه من بكورتيكوستيرويد الإضافية مثل إبيزولون - ديبو يمكنه المساعدة عندما يتم حقنها في الجسم عن طريق الطبيب أو الممرضة، في أو بالقرب من المفصل، للعلاج الموضعي.</p><p dir="RTL" style="text-align:right">للأعراض الناجمة عن حالات الالتهابات الروماتيزمية أو مثل:</p><p dir="RTL" style="text-align:right">- إلتهاب الجراب: الالتهاب في السائل الموجود حول الكتف والركبة و / أو مفاصل الكوع. و لهذه الحالة يتم حقن الدواء مباشرة في إحدى أو أكثر من هذه مساحات.</p><p dir="RTL" style="text-align:right">- هشاشة العظام والتهاب المفاصل الروماتيزمي: الالتهاب الموجود بين المفاصل. وبالنسبة لهذه الحالات يتم حقن هذا الدواء مباشرة في المساحه المحيطه بالمفصل أو يتم الحقن في أكثر من موضع واحد.</p><p dir="RTL" style="text-align:right">- التهاب اللفافة الأخمصية: التهاب في أنسجة اسفل القدم.</p><p dir="RTL" style="text-align:right">- مشاكل الجلد: مثل داء الثعلبة (الصلع غير مكتمل)، الجدرة(النسيج الندبي)، مرض الحزاز المسطح أو البسيط (أثار بقع صغيرة من الجلد أو بقع أرجوانيه)، الذئبة القرصية (بقع مستديرة الشكل تظهر في كثير من الأحيان على الوجه), أو الورم الحبيبي الحلقي( زوائد دائريه ممتلئه بالبثور).</p><p dir="RTL" style="text-align:right">- التهاب اللقيمة (الكوع) و التهاب غمد الوتر: عند حدوث مثل هذه الحالات سيتم حقن الدواء في غمد الوتر.</p><p dir="RTL" style="text-align:right">كبديل لهذا الدواء قد يتم حقنه في العضل للمساعدة في علاج المزيد من المشاكل العامه(الجهازيه) التي تؤثر على الجسم كله, على سبيل المثال الأعراض الناجمة عن زياده التحسسيه&nbsp; إلى الدواء , أو مشاكل الحساسية، الالتهابات أو الروماتيزم التي تؤثر على:</p><p dir="RTL" style="text-align:right">- مثل المخ التهاب السحايا الناجم عن مرض السل.</p><p dir="RTL" style="text-align:right">- الأمعاء والقناة الهضمية مثل داء كرون (التهاب الأمعاء أو التهاب القولون التقرحي (التهاب القولون السفلي).</p><p dir="RTL" style="text-align:right">- المفاصل على سبيل المثال التهاب المفاصل الروماتيزمي.</p><p dir="RTL" style="text-align:right">- الرئتين مثل الربو والحمي الموسميه والتهاب الأنف الحاد أو السل أو الالتهاب الناجم عن التنفس في شفط القيء أو محتويات المعدة</p><p dir="RTL" style="text-align:right">- الجلد مثل متلازمة ستيفنز جونسون (اضطراب المناعة الذاتية التي يسبب فيها الجهاز المناعي بثور وقشور للجلد) أو الذئبة الحمامية الجهازية (مرض الذئبة).</p><p dir="RTL" style="text-align:right">طبيبك قد يستخدم هذا الدواء لعلاج أمراض أخرى غير تلك المذكورة أعلاه.</p><p dir="RTL" style="text-align:right">اسأل طبيبك إذا كنت غير متأكد لماذا أعطيت هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">لا تستخدم إبيزولون - ديبو إذا:</p><p dir="RTL" style="text-align:right">- إذا تعرضت من أي وقت مضى للحساسية، أو أي نوع آخر من رد فعل بعد أخذ إبيزولون &ndash; ديبو ، أو أي دواء آخر يحتوي على كورتيكوستيرويد أو أي من المكونات في هذا الدواء (المادة 6 من هذه النشرة يحتوي على قائمة من المكونات ). قد تسبب الحساسية والطفح الجلدي أو احمرار، تورم الوجه أو الشفتين أو ضيق في التنفس.</p><p dir="RTL" style="text-align:right">- قد تعاني من الطفح الجلدي، أو أعراض أخرى للعدوى.</p><p dir="RTL" style="text-align:right">راجع طبيبك فورا إذا كانت تعاني اي مما سبق .</p><p dir="RTL" style="text-align:right">لا تقم بحقن هذا الدواء في:</p><p dir="RTL" style="text-align:right">- في وتر العرقوب (الذي يقع خلف مفصل الكاحل)، أو</p><p dir="RTL" style="text-align:right">- مباشرة في الوريد، والحبل الشوكي(داخل الغمد)، والجزء الخارجي من الدماغ(خارج الجافية)، في فتحتي الأنف (داخل الأنف) أو في العين (في المقله).</p><p dir="RTL" style="text-align:right">يجب توخي الحذر قبل أخذ إبيزولون - ديبو:</p><p dir="RTL" style="text-align:right">يجب أن تخبر طبيبك قبل أخذ هذا الدواء إذا تعاني من الحالات التاليه.</p><p dir="RTL" style="text-align:right">قد يجب علي طبيبك أيضا لمراقبة العلاج عن كثب، تغيير الجرعة أو يعطيك دواء آخر.</p><p dir="RTL" style="text-align:right">- قصور الغدة الكظرية الحاد (عندما لا ينتج جسمك الكورتيكوستيرويدات بما فيه الكفاية بسبب مشاكل في الغدد الكظرية).</p><p dir="RTL" style="text-align:right">- التهاب البنكرياس الحاد (التهاب البنكرياس).</p><p dir="RTL" style="text-align:right">- الجديري المائي، القوباء المنطقية أو عدوى الهربس بالعين. إذا كنت تعتقد أنك تم الاتصال مع شخص مصاب بجدري الماء أو القوباء المنطقية ولم يكن لديك بالفعل هذه الأمراض، أو إذا كنت غير متأكد إذا كان لديك هذه الأمراض.</p><p dir="RTL" style="text-align:right">- الاكتئاب الشديد أو الاكتئاب الهوسي (اضطراب ثنائي القطب). ويشمل ذلك إذ كان الاكتئاب قبل في حين أخذ أدوية الستيرويد مثل إبيزولون - ديبو ، أو وجود تاريخ عائلي من هذه الأمراض.</p><p dir="RTL" style="text-align:right">- مرض السكري (أو إذا كان هناك تاريخ عائلي من مرض السكري).</p><p dir="RTL" style="text-align:right">- الصرع.</p><p dir="RTL" style="text-align:right">- المياه الزرقاء (ارتفاع الضغط في العين) أو إذا كان هناك تاريخ عائلي من المياه الزرقاء.</p><p dir="RTL" style="text-align:right">- إذا كنت قد تعرضت مؤخرا لنوبة قلبية.</p><p dir="RTL" style="text-align:right">- مشاكل في القلب، بما في ذلك فشل القلب أو الاصابه بالعدوي.</p><p dir="RTL" style="text-align:right">- ارتفاع الضغط (إرتفاع ضغط الدم).</p><p dir="RTL" style="text-align:right">- الغدة الدرقية (وهي الغدة الدرقية تحت النشطة).</p><p dir="RTL" style="text-align:right">- عدوى المفصل.</p><p dir="RTL" style="text-align:right">- أمراض الكبد او الكلى.</p><p dir="RTL" style="text-align:right">- أن يحدث مشاكل في العضلات (ألم أو ضعف)، في حين أخذ أدوية الستيرويد في الماضي.</p><p dir="RTL" style="text-align:right">- الوهن العضلي الشديد (وهي حالة تسبب العضلات وتعب وضعف العضلات ).</p><p dir="RTL" style="text-align:right">- هشاشة العظام (عظام هشة).</p><p dir="RTL" style="text-align:right">-ورم القواتم (ورم نادر من النسيج الغدة الكظرية وتقع الغدد الكظرية فوق الكلى).</p><p dir="RTL" style="text-align:right">- خراج الجلد.</p><p dir="RTL" style="text-align:right">- قرحة المعدة أو غيرها من المشاكل الخطيرة في المعدة أو الأمعاء .</p><p dir="RTL" style="text-align:right">- التهاب الوريد التجلطي - مشاكل الوريد بسبب تجلط الدم (تجلط في الأوردة) مما أدى إلى التهاب الأوردة&nbsp; (أحمرار، تورم وضعف الاورده).</p><p dir="RTL" style="text-align:right">- السل أو إذا كنت قد تعرضت للسل في الماضي.</p><p dir="RTL" style="text-align:right">- إصابات في الدماغ.</p><p dir="RTL" style="text-align:right">&nbsp; يجب أن تخبر طبيبك قبل أخذ هذا الدواء إذا كان لديك أي من الحالات التي سبق ذكرها.</p><p dir="RTL" style="text-align:right">أخذ أدوية أخرى:</p><p dir="RTL" style="text-align:right">أخبر دائما طبيبك أو الصيدلي إذا كنت تأخذ أي أدوية (بما في ذلك أي أدويه قمت بشرائها بدون وصفة طبية)، وأخذ إبيزولون-ديبو مع أدوية أخرى قد يكون ضار.</p><p dir="RTL" style="text-align:right">يجب أن تخبر طبيبك إذا كنت تأخذ أي من الأدوية التالية التي يمكن أن تؤثر على طريقه عمل إبيزولون - ديبو أو طريقه عمل الادويه الاخري :</p><p dir="RTL" style="text-align:right">- الأسيتازولاميد - يستخدم لعلاج المياه الزرقاء والصرع</p><p dir="RTL" style="text-align:right">- أمينوجلوتيثيميد - يستخدم لعلاج السرطان</p><p dir="RTL" style="text-align:right">- مضادات البكتيريا (مثل أيزونيازيد، الاريثروميسين، كلاريثروميسين و ترولاندوميسين).</p><p dir="RTL" style="text-align:right">- مضادات التجلط - تستخدم لترقيق الدم مثل أسينوكومارول، فينينديون والوارفارين</p><p dir="RTL" style="text-align:right">- مضادات الكوليستيرينيز,يستخدم لعلاج الوهن العضلي الوبيل (حالة مرضيه للعضلات) مثل دايجستمين ونيوستيجمين.</p><p dir="RTL" style="text-align:right">- مضادات السكري(الأدوية المستخدمة لعلاج ارتفاع نسبة السكر في الدم).</p><p dir="RTL" style="text-align:right">- المضادات للقئ (مثل أبريبيتانت و فوسابريبيتانت).</p><p dir="RTL" style="text-align:right">- الأسبرين و الأدوية المضادة للالتهابات الغير الستيرويدية (وتسمى أيضا المسكنات)، مثل ايبوبروفين تستخدم لعلاج آلام خفيفة إلى متوسطة.</p><p dir="RTL" style="text-align:right">- الباربيتورات، كاربامازيبين، فينيتوين والبريميدون - يستخدم لعلاج الصرع.</p><p dir="RTL" style="text-align:right">- كربينوكسولون - تستخدم لعلاج الحموضه المعويه وعسر الهضم الحمضي.</p><p dir="RTL" style="text-align:right">- سيكلوسبورين - يستخدم لعلاج أمراض مثل التهاب المفاصل الروماتويدي الحاد، أو مرض الصدفية أو بعد عمليه زراعه الاعضاء أو نخاع عظام.</p><p dir="RTL" style="text-align:right">- الديجوكسين - تستخدم لقصور القلب و / أو عدم انتظام ضربات القلب.</p><p dir="RTL" style="text-align:right">- الديلتيازيم أو ميبيفراديل - تستخدم لمشاكل في القلب أو ارتفاع ضغط الدم.</p><p dir="RTL" style="text-align:right">- إيثينيل استراديول و نوريثيندرون (وسائل منع الحمل عن طريق الفم).</p><p dir="RTL" style="text-align:right">- إندينافير وريتونافير (تستخدم لعلاج عدوى فيروس نقص المناعه البشري).</p><p dir="RTL" style="text-align:right">- الكيتوكونازول أو الايتراكونازول - يستخدم لعلاج الالتهابات الفطرية</p><p dir="RTL" style="text-align:right">- بانكورونيوم - أو غيرها من الأدوية تسمى عوامل منع توصيل الاعصاب. التي تستخدم في بعض العمليات الجراحية</p><p dir="RTL" style="text-align:right">- عوامل استنفاذ البوتاسيوم - مثل مدرات البول (تسمى أحيانا أقراص المياه)، أمفوتيريسين ب، زانثينيس أو منبهات البيتا٢ (مثل الأدوية المستخدمة لعلاج الربو).</p><p dir="RTL" style="text-align:right">- ريفامبيسين وريفابيتين - المضادات الحيوية المستخدمة لعلاج السل</p><p dir="RTL" style="text-align:right">- تاكروليموس - تستخدم بعد زرع الأعضاء لمنع رفض الأعضاء.</p><p dir="RTL" style="text-align:right">- التطعيم - أخبر طبيبك إذا كنت قد أخذت مؤخرا، أو تكون على وشك أن تأخذ أي تطعيم. يجب أن لا تأخذ لقاحات &#39;حية&#39; أثناء استخدام هذا الدواء. قد تكون اللقاحات الأخرى أقل فعالية.</p><p dir="RTL" style="text-align:right">إذا كنت تأخذ الدواء على المدى الطويل</p><p dir="RTL" style="text-align:right">إذا كنت تتعالج من مرض السكر، وارتفاع ضغط الدم أو احتباس الماء (إستسقاء الجلد) أخبر طبيبك كما انه قد يحتاج إلى ضبط جرعة الأدوية المستخدمة في علاج هذه الحالات.</p><p dir="RTL" style="text-align:right">قبل أن تقوم بأي عملية أخبر طبيبك أو طبيب الأسنان أو أخصائي التخدير أنك تأخذ هذا الدواء.</p><p dir="RTL" style="text-align:right">إذا كنت تحتاج إلى اختبار يقوم به الطبيب أو في المستشفى من المهم أن تخبر الطبيب أنك تأخذ إبيزولون - ديبو. هذا الدواء يمكن أن يؤثر على نتائج بعض الاختبارات.</p><p dir="RTL" style="text-align:right">إبيزولون - ديبو مع الشراب:</p><p dir="RTL" style="text-align:right">لا تشرب عصير الجريب فروت أثناء تناول هذا الدواء.</p><p dir="RTL" style="text-align:right">الحمل والرضاعة:</p><p dir="RTL" style="text-align:right">يجب إخبار الطبيب إذا كنت حاملا، تعتقدين أنك قد تكون حاملا أو تحاولين أن تصبحين حاملا لأن هذا الدواء قد يبطئ نمو الطفل.</p><p dir="RTL" style="text-align:right">وقد لوحظ إعتام عدسة العين عند الرضع الذين يولدون لأمهات تتعالج بواسطة الكورتيكوستيرويدات طويلة الأجل خلال فترة الحمل.</p><p dir="RTL" style="text-align:right">أخبر طبيبك إذا كنت تقومين الرضاعة الطبيعية كميات صغيرة من كورتيكوستيرويدات قد تصل إلى حليب الثدي.</p><p dir="RTL" style="text-align:right">إذا تابعت الرضاعة الطبيعية بينما كنت تأخذين العلاج، سوف طفلك يحتاج فحوصات إضافية للتأكد من انه أو انها لا تتأثر الدواء.</p><p dir="RTL" style="text-align:right">القيادة واستخدام الآليات:</p><p dir="RTL" style="text-align:right">لا توجد احتياطات خاصة أثناء أخذ هذا الدواء.</p><p dir="RTL" style="text-align:right">إبيزولون - ديبو يحتوي على الصوديوم</p><p dir="RTL" style="text-align:right">هذا المنتج الطبي يحتوي على أقل من ١ مليمول الصوديوم (٢٣ مجم) في الفيال، أي خالية من الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">معلومات دوائيه:</p><p dir="RTL" style="text-align:right">طبيبك سوف يقرر موقع الحقن، وكميه الدواء وعدد الحقن التي سوف تتلقاها تبعا للحالة المرضيه و حدتها. طبيبك سوف بحقنك بأقل جرعة لأقصر وقت ممكن للحصول على الراحه الفعالة من الأعراض الخاصة بك.</p><p dir="RTL" style="text-align:right">البالغين:</p><p dir="RTL" style="text-align:right">طبيبك سوف يقوم بإخبارك كم الحقن التي سوف تحتاجها لطبقاً لحالة المرضيه ومتى ستحصل عليها.</p><p dir="RTL" style="text-align:right">المفاصل - فإن الجرعة العادية للحقن في المفاصل يعتمد على حجم المفصل. المفاصل الكبيرة ، مثل الركبة والكاحل والكتف( قد تتطلب ٢٠-٨٠ مجم&nbsp; ) ٠.٥ مل - ٢ مل.</p><p dir="RTL" style="text-align:right">المفاصل متوسطة الحجم مثل الكوع أو الرسغ ( ١٠- ٤٠ مجم) ٠.٢٥ ملم - ١ ملم، والمفاصل الصغيرة, على سبيل المثال الأصابع أو مفاصل اصابع القدمين ( قد يتطلب ٤-١٠ مجم&nbsp; ٠.١- ٠.٢٥ للجرعة).</p><p dir="RTL" style="text-align:right">يمكن إعطاء حقن المفاصل أسبوعيًا على مدار عدة أسابيع ، اعتمادًا على مدى سرعة استجابتك للعلاج.</p><p dir="RTL" style="text-align:right">التهاب الجراب والتهاب اللقيمة (مرفق التنس) - تتراوح الجرعة المعتادة بين ٤ - ٣٠ مجم ( ٠.١ - ٠.٧٥ مل). في معظم الحالات ، لن تكون هناك حاجة لتكرار الحقن في حالة التهاب الجراب والتهاب اللقيمة ، وقد يكون تكرار الحقن ضروريًا لعلاج الحالات طويلة الأمد.</p><p dir="RTL" style="text-align:right">الأمراض الجلدية - الجرعة المعتادة هي ٢٠ - ٦٠ مجم ( ٠.٥ - ١.٥ مل) تحقن في الجزء المصاب أو الأجزاء المصابة من الجلد.</p><p dir="RTL" style="text-align:right">للحالات العامة الأخرى يمكن حقن ٤٠ - ١٢٠ مجم ( ١ - ٣ مل) من هذا الدواء في العضلة الكبيرة.</p><p dir="RTL" style="text-align:right">كبار السن</p><p dir="RTL" style="text-align:right">والعلاج يكون عادةً كالبالغين الأصغر سناً. ومع ذلك فإن طبيبك قد يطلب أن يراك أكثر انتظاما للتحقق من مدى استجابتك للعلاج .</p><p dir="RTL" style="text-align:right">الأطفال</p><p dir="RTL" style="text-align:right">يمكن الكورتيزون يؤثر على النمو في الأطفال حتى الطبيب سيصف أقل جرعة تكون فعالة لطفلك.</p><p dir="RTL" style="text-align:right">إذا أخذت إبيزولون - ديبو أكثر مما يجب:</p><p dir="RTL" style="text-align:right">إذا كنت تعتقد أنك قد أعطيت الكثير من حقن يرجى التحدث إلى الطبيب على الفور.</p><p dir="RTL" style="text-align:right">وقف / التقليل من جرعة إبيزولون - ديبو:</p><p dir="RTL" style="text-align:right">طبيبك سوف يحدد الموقت المناسب لوقف العلاج.</p><p dir="RTL" style="text-align:right">وسوف تحتاج لوقف هذا العلاج ببطء إذا كنت:</p><p dir="RTL" style="text-align:right">- قد أعطيت إبيزولون - ديبو لأكثر من ٣ أسابيع؛</p><p dir="RTL" style="text-align:right">- تم إعطاؤك جرعات عالية من إبيزولون-ديبو ، أكثر من ٣٢ مجم ( ٠.٨ مل) يوميًا ، حتى لو كانت لمدة ٣ أسابيع فقط أو أقل ؛</p><p dir="RTL" style="text-align:right">- إذاقمت بالفعل بأخذ دورة من الأقراص أو الحقن من كورتيكوستيرويدات في العام الماضي.</p><p dir="RTL" style="text-align:right">- لديك بالفعل مشاكل مع الغدد الكظرية(قصور قشرة الكظر) قبل أن تبدأ هذا العلاج.</p><p dir="RTL" style="text-align:right">وسوف تحتاج لوقف العلاج&nbsp; ببطء لتجنب أعراض الإنسحاب.</p><p dir="RTL" style="text-align:right">ويمكن أن تشمل هذه الأعراض حكة فى الجلد، والحمى وآلام في المفاصل والعضلات ، وسيلان الأنف ولزوجه العينين ، والتعرق وفقدان الوزن.</p><p dir="RTL" style="text-align:right">إذا بدأت الأعراض للعودة أو إذدادت سوءاً مع تقليل الجرعة أخبر طبيبك فورا.</p><p dir="RTL" style="text-align:right">المشاكل العقلية مع إبيزولون-ديبو:</p><p dir="RTL" style="text-align:right">مشاكل الصحة العقلية يمكن أن يحدث أثناء تناول الستيرويدات مثل إبيزولون-ديبو انظر أيضا الجزء:٤-الآثار الجانبية المحتملة.</p><p dir="RTL" style="text-align:right">-&nbsp; هذه الأمراض يمكن أن تكون خطيرة.</p><p dir="RTL" style="text-align:right">-&nbsp; وعادة ما تبدأ في خلال أيام قليلة أو أسابيع من بدء العلاج.</p><p dir="RTL" style="text-align:right">- هذه الاعراض أكثر حدوثاً في الجرعات العالية.</p><p dir="RTL" style="text-align:right">- معظم هذه المشاكل تختفي إذا تم خفض الجرعة أو إيقاف الدواء. ولكن إذا حدثت المشاكل فقد تحتاج إلى علاج.</p><p dir="RTL" style="text-align:right">تحدث إلى طبيبك إذا كنت (أو شخص ما يستخدم هذا الدواء) يظهر عليه أي بوادر مشاكل عقلية. هذا مهم بشكل خاص إذا كنت مكتئبا، أو قد فكرت في الانتحار. وفي حالات قليلة قد يحدث مشاكل عقلية عند تخفيض الجرعات أو وقفها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">مثل جميع الستيرويدات هذا الدواء يمكن أن يسبب آثار جانبية، على الرغم من أنها لا تحدث للجميع .سوف يقوم طيبيك بإعطائك هذا الدواء لعلاج حاله محدده وإن يم يتم علاجها بطريقه صحيحه فقد يكون خطيراً.</p><p dir="RTL" style="text-align:right">في بعض الظروف الطبية أدوية مثل إبيزولون - ديبو(الستيرويدات) لا ينبغي أن تقوم بوقف العلاج فجأة، إذا كنت تعاني من أي من الأعراض التالية يجب الحصول على الرعاية الطبية الفورية، الطبيب سوف يقرر إذا ما كان يجب متابعة أخذ الدواء الخاص بك:</p><p dir="RTL" style="text-align:right">-&nbsp; الحساسية، مثل الطفح الجلدي، وتورم في الوجه أو الأزيز أثناء التنفس وصعوبة في التنفس. هذا النوع من الآثار الجانبية نادر الحدوث، ولكن قد يكون خطيرا.</p><p dir="RTL" style="text-align:right">-&nbsp; التهاب البنكرياس الحاد وآلام في المعدة تمتد الى ظهرك، وربما يصاحبه قيء أو صدمة وفقدان الوعي.</p><p dir="RTL" style="text-align:right">- القرحة أو نزيف القرحة، و أعراض منها آلام حادة في المعدة والتي قد تمد الي الظهر ويمكن أن تترافق مع نزيف من الدبر، براز أسود أو ملطخ بالدماء و / أو تقيئ دم.</p><p dir="RTL" style="text-align:right">- التهابات. هذا الدواء يستطيع إخفاء أو تغيير علامات وأعراض بعض الأمراض، أو تقليل المقاومه للعدوى، بحيث من الصعب التشخيص في مرحلة مبكرة. ويمكن أن تشمل الأعراض ارتفاع في درجة الحرارة و الشعور بالإعياء. أعراض مندلعه من عدوى السل السابق قد يكون السعال مصاحب بالدم أو ألم في الصدر. هذا الدواء قد يجعلك أكثر عرضة للعدوى الحاده.</p><p dir="RTL" style="text-align:right">- التهاب الغشاء البرتوني، التهاب(تهيج) الغشاء البرتوني، الأنسجة الرقيقة التي ترسم الجدار الداخلي للبطن وتغطي معظم أعضاء البطن. الأعراض هي الم&nbsp; شديد بالمعدة&nbsp; أو الم خفيف ، الألم قد يصبح أسوأ عندما يتم لمس المعدة أو عند التحرك.</p><p dir="RTL" style="text-align:right">- الصمة الرئوية (تجلط الدم في الرئة) الأعراض تشمل ألم حاد في الصدر فجأة، ضيق في التنفس وسعال الدم.</p><p dir="RTL" style="text-align:right">- ارتفاع الضغط داخل الجمجمة الأطفال( ورم الدماغي الكاذب) من الأعراض الصداع مع التقيؤ، ونقص الطاقة والنعاس. عادة ما تحدث هذه الآثار الجانبية بعد إيقاف العلاج.</p><p dir="RTL" style="text-align:right">- التهاب الوريد التجلطي(الجلطات الدموية أو تجلط الدم في وريد الساق) فإن الأعراض تشمل ورم وإحمرار والام الأوردة.</p><p dir="RTL" style="text-align:right">إذا كنت تواجه أي من الآثار الجانبية التالية، أو لاحظت أي آثار غير عادية أخرى لم يرد ذكرها في هذه النشرة، أخبر طبيبك فورا.</p><p dir="RTL" style="text-align:right">وقد تحدث الآثار الجانبية بترددات معينة، تعرف على النحو التالي:</p><p dir="RTL" style="text-align:right">- غير معروف: لا يمكن تقدير التردد من البيانات المتاحة.</p><p dir="RTL" style="text-align:right">الدم والقلب والدورة الدموية:</p><p dir="RTL" style="text-align:right">غير معروف:</p><p dir="RTL" style="text-align:right">- ارتفاع ضغط الدم، وأعراضه هي الصداع، أو الشعور عموما بانك لست على ما يرام.</p><p dir="RTL" style="text-align:right">- مشاكل في ضخ قلبك (قصور القلب)أعراض التي تورم الكاحلين، وصعوبة في التنفس والخفقان (الشعور بضربات القلب) أو ضربات غير منتظمة للقلب، وعدم انتظام أو سريع جدا أو نبض بطيء.</p><p dir="RTL" style="text-align:right">- انخفاض ضغط الدم، والأعراض قد تشمل الدوخة، والإغماء، والدوار، وعدم وضوح الرؤية، وسرعة أو عدم انتظام ضربات القلب (خفقان).</p><p dir="RTL" style="text-align:right">- زيادة خلايا الدم البيضاء(زيادة عدد الكريات البيضاء).</p><p dir="RTL" style="text-align:right">- زيادة تخثر الدم.</p><p dir="RTL" style="text-align:right">ماء الجسم والأملاح:</p><p dir="RTL" style="text-align:right">غير معروف:</p><p dir="RTL" style="text-align:right">- تورم وارتفاع ضغط الدم، والناجمة عن زيادة مستويات كمية المياه والملح.</p><p dir="RTL" style="text-align:right">- تشنجات وتقلصات، ويرجع ذلك إلى فقدان البوتاسيوم من الجسم. في حالات نادرة يمكن أن يؤدي هذا إلى فشل القلب الاحتقاني (عندما يكون القلب غير قادر علي الضخ الصحيح).</p><p dir="RTL" style="text-align:right">الجهاز الهضمي:</p><p dir="RTL" style="text-align:right">غير معروف:</p><p dir="RTL" style="text-align:right">- قرحة</p><p dir="RTL" style="text-align:right">- غثيان (شعور بالمرض) أو التقيؤ (الإحساس بالمرض).</p><p dir="RTL" style="text-align:right">- ارتجاع في المريء (عدم الراحة على البلع).</p><p dir="RTL" style="text-align:right">- عسر الهضم.</p><p dir="RTL" style="text-align:right">- إسهال</p><p dir="RTL" style="text-align:right">&nbsp;- المعدة المتضخمة.</p><p dir="RTL" style="text-align:right">- الم في المعده - قرحة المعدة أو مرض القلاع في المريء (عدم الراحة عند البلع).</p><p dir="RTL" style="text-align:right">- الفواقات المستمرة، وخصوصا عندما تؤخذ جرعات عالية.</p><p dir="RTL" style="text-align:right">الاذن:</p><p dir="RTL" style="text-align:right">غير معروف:</p><p dir="RTL" style="text-align:right">- الشعور بالدوخه أو الدوران(الدوار).</p><p dir="RTL" style="text-align:right">العيون:</p><p dir="RTL" style="text-align:right">غير معروف:</p><p dir="RTL" style="text-align:right">- إعتام عدسة العين (المشار إليها بفشل البصر).</p><p dir="RTL" style="text-align:right">- المياه الزرقاء(ارتفاع الضغط داخل العين، مما يسبب ألم في العينين والصداع).</p><p dir="RTL" style="text-align:right">- تورم العصب البصري (يسبب حالة تسمى القرص البصري، والذي قد يسبب اضطراب الرؤيه).</p><p dir="RTL" style="text-align:right">- زيادة الضغط داخل العين، مع الأضرار المحتملة للعصب البصري (المشار إليها بالفشل البصري).</p><p dir="RTL" style="text-align:right">- ترقق جزء واضح في الجزء الأمامي من العين (القرنية) أو من الجزء الأبيض من العين (الصلبة في العين).</p><p dir="RTL" style="text-align:right">- تفاقم الالتهابات الفيروسية أو الفطرية العين.</p><p dir="RTL" style="text-align:right">- جحوظ من مقل العيون (جحوظ العين).</p><p dir="RTL" style="text-align:right">- الرؤية غير واضحة أو مشوهة(بسبب مرض شبكية العين وغشاء المشيمية).</p><p dir="RTL" style="text-align:right">اضطرابات عامة:</p><p dir="RTL" style="text-align:right">غير معروف:</p><p dir="RTL" style="text-align:right">- ضعف التئام الجروح.</p><p dir="RTL" style="text-align:right">- التهيج لدى الأطفال.</p><p dir="RTL" style="text-align:right">- الشعور بالتعب أو انك لست علي ما يرام.</p><p dir="RTL" style="text-align:right">- ردود فعل الجلد التحسسي في موقع الحقن.</p><p dir="RTL" style="text-align:right">- التهيج لدى البالغين.</p><p dir="RTL" style="text-align:right">اضطرابات الكبد</p><p dir="RTL" style="text-align:right">- ميثيلبرديسولون يمكن أن تتلف الكبد، والتهاب الكبد وزيادة إنزيمات الكبد قد تم الإبلاغ عنها.</p><p dir="RTL" style="text-align:right">الهرمونات ونظام التمثيل الغذائي:</p><p dir="RTL" style="text-align:right">غير معروف:</p><p dir="RTL" style="text-align:right">- تباطؤ النمو الطبيعي عند الرضع والأطفال والمراهقين والتي قد تكون دائمة.</p><p dir="RTL" style="text-align:right">- وجه مستدير أو على شكل القمر (وجوه كوشينغ).</p><p dir="RTL" style="text-align:right">- مرض السكري أو تفاقم حاله مرض السكري القائم.</p><p dir="RTL" style="text-align:right">- عدم انتظام أو توقف فترة الطمث في النساء.</p><p dir="RTL" style="text-align:right">- زيادة الشهية وزيادة الوزن.</p><p dir="RTL" style="text-align:right">- التراكم الغير طبيعي للدهون أو قد تشبه&nbsp; الورم&nbsp; في الأنسجة.</p><p dir="RTL" style="text-align:right">- العلاج المطول يمكن أن يؤدي إلى انخفاض مستويات بعض الهرمونات والتي بدورها يمكن أن يسبب انخفاض ضغط الدم والدوخة. قد يستمر هذا التأثير لعدة أشهر.</p><p dir="RTL" style="text-align:right">- كمية بعض المواد الكيميائية (الإنزيمات) التي تسمي ناقلة ألانين ترانس امينيز، اسبارتات ترانس امينيز والفوسفاتيز القلوية التي تساعد الجسم على هضم الأدوية وغيرها من المواد في الجسم قد ترتفع بعد العلاج مع كورتيكوستيرويدات. التغيير عادة ما يكون صغير ومستويات الانزيمات تعود إلى حالتها الطبيعية بعد إخراج الادوية بشكل طبيعي من النظام. أنك لن تلاحظ أي أعراض إذا حدث هذا، ولكنها سوف تظهر إذا قمت بعمل اختبار الدم.</p><p dir="RTL" style="text-align:right">جهاز المناعة:</p><p dir="RTL" style="text-align:right">غير معروف:</p><p dir="RTL" style="text-align:right">- زيادة الاستعداد للإصابه للعدوي التي يمكن ان تخفي أو تغيير ردود فعل طبيعية لاختبارات الجلد، مثل السل.</p><p dir="RTL" style="text-align:right">التمثيل الغذائي و اضطرابات التغذية :</p><p dir="RTL" style="text-align:right">- تراكم الأنسجة الدهنية على أجزاء موضعيه من الجسم.</p><p dir="RTL" style="text-align:right">العضلات والعظام والمفاصل:</p><p dir="RTL" style="text-align:right">غير معروف:</p><p dir="RTL" style="text-align:right">- ضعف العضلات .</p><p dir="RTL" style="text-align:right">-&nbsp; هشاشة العظام (كسر العظام بسهولة)</p><p dir="RTL" style="text-align:right">- خسارة العضلات .</p><p dir="RTL" style="text-align:right">-&nbsp; كسر العظام .</p><p dir="RTL" style="text-align:right">-&nbsp; انهيار العظام نتيجة لضعف الدورة الدموية في الدم، وهذا يسبب ألم في الورك.</p><p dir="RTL" style="text-align:right">-&nbsp; تمزق أوتار العضلات تسبب الألم و / أو الورم.</p><p dir="RTL" style="text-align:right">الام في المفاصل:</p><p dir="RTL" style="text-align:right">-&nbsp; تشنجات أو تقلصات العضلات.</p><p dir="RTL" style="text-align:right">-&nbsp; تورم أو آلام المفاصل بسبب الإصابة بالعدوي.</p><p dir="RTL" style="text-align:right">الأعصاب و مشاكل&nbsp; الحالة المزاجية:</p><p dir="RTL" style="text-align:right">غير معروف:</p><p dir="RTL" style="text-align:right">&nbsp;الاستيرويدات بما في ذلك ميثيل بريدنيزولون يمكن أن يسبب مشاكل صحية عقلية خطيرة. و هي شائعة في كل من البالغين والأطفال. ويمكن أن يؤثر على حوالي ٥ في كل ١٠٠ من الأشخاص الذين يتناولون أدوية مثل ميثيل بريدنيزولون.</p><p dir="RTL" style="text-align:right">- الشعور بالاكتئاب، بما في ذلك التفكير في الانتحار.</p><p dir="RTL" style="text-align:right">- الشعور بالإنتشاء(الهوس) أو الحالة المزاجية التي تستمر صعودا وهبوطا.</p><p dir="RTL" style="text-align:right">- الشعور بالقلق، وجود مشاكل في النوم، وصعوبة في التفكير أو الشعور بالحيره وفقدان الذاكرة الخاصة بك.</p><p dir="RTL" style="text-align:right">- الشعور، ورؤية أو سماع أشياء&nbsp; لا وجود لها. وجود أفكار غريبة ومخيفة، وتغيير الطريقة التي يتصرف أو الإحساس بالوحده.</p><p dir="RTL" style="text-align:right">- الآثار العصبية الأخرى قد تشمل التشنجات (النوبات)، فقدان الذاكرة، واضطراب الإدراك (التغيرات العقلية، والدوخة والصداع).</p><p dir="RTL" style="text-align:right">- آلام الظهر أو ضعفه (بسبب إبيدورال ليبوماتوسيس، وهو اضطراب نادر التي تخزن كمية غير طبيعية من الدهون على أو خارج بطانة العمود الفقري).</p><p dir="RTL" style="text-align:right">الجلد</p><p dir="RTL" style="text-align:right">-&nbsp; حب الشباب.</p><p dir="RTL" style="text-align:right">-&nbsp; كدمات.</p><p dir="RTL" style="text-align:right">-&nbsp; الخراج، وخصوصا بالقرب من مواقع حقن</p><p dir="RTL" style="text-align:right">-&nbsp; ترقق الجلد مع علامات التمدد.</p><p dir="RTL" style="text-align:right">-&nbsp; بقع أرجوانية / حمراء صغيرة على الجلد.</p><p dir="RTL" style="text-align:right">-&nbsp; بقع شاحبة أو أغمق على جلدك، أو ظهور البقع لها لون غير عادي.</p><p dir="RTL" style="text-align:right">- زياده الشعر علي الجسم و الوجه(كثره الشعر).</p><p dir="RTL" style="text-align:right">- طفح جلدي، حكة، ارتكاريا.</p><p dir="RTL" style="text-align:right">- زيادة التعرق.</p><p dir="RTL" style="text-align:right">إذا كنت تواجه أي من الآثار الجانبية المذكورة أعلاه أخبر طبيبك مباشرة على الفور.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">يجب عدم استخدام هذا الدواء بعد تاريخ انتهاء الصلاحية المبين على العلبه.</p><p dir="RTL" style="text-align:right">يجب تخزين هذا الدواء في درجه حراره لا تزيد عن ٣٠ &deg;، ولكن يجب عدم تجميد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">المادة الفعالة: أسيتات الميثيل بريدنيزولون.</p><p dir="RTL" style="text-align:right">يحتوى كل ملليلتر من الدواء علي ٤٠ مجم من أسيتات الميثيل بريدنيزولون .</p><p dir="RTL" style="text-align:right">المواد الغير فعالة:</p><p dir="RTL" style="text-align:right">كلوريد الصوديوم، بولى إيثيلين جليكول، كلوريد البنزيثونيوم، هيدروكسيد الصوديوم ، حمض الهيدروكلوريك و ماء معد للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">العبوة:&nbsp;&nbsp;&nbsp;</p><p dir="RTL" style="text-align:right">علبة تحتوى على فيال ١ أو ٢ ملليلتر و النشرة الداخلية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة المصرية الدولية للصناعات الدوائية (إيبيكو)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر ٢٠٢٢
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EPIZOLONE DEPOT 40 mg Vial
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml contains:
Methyl prednisolone acetate	40 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Suspension for Injection.
 A homogenous sterile suspension filled in a colorless glass vials.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:-44.7pt">Epizolone Depot may be used locally or systemically, particularly where oral therapy is not feasible.</p><p style="margin-right:-44.7pt">Epizolone Depot may be used by any of the following routes: intramuscular, intra-articular, periarticular, intrabursal, intralesional or into the tendon sheath. It must not be used by the intrathecal or intravenous routes (see Contra-indications and Undesirable effects).</p><p style="margin-right:-44.7pt">Intramuscular administration:</p><p style="margin-right:-44.7pt">1. Rheumatic disorders</p><p style="margin-right:-44.7pt">Rheumatoid arthritis</p><p style="margin-right:-44.7pt">2. Collagen diseases/arteritis</p><p style="margin-right:-44.7pt">Systemic lupus erythematosus</p><p style="margin-right:-44.7pt">3. Dermatological diseases</p><p style="margin-right:-44.7pt">Severe erythema multiforme (Stevens-Johnson syndrome)</p><p style="margin-right:-44.7pt">4. Allergic states</p><p style="margin-right:-44.7pt">Bronchial asthma</p><p style="margin-right:-44.7pt">Severe seasonal and perennial allergic rhinitis</p><p style="margin-right:-44.7pt">Drug hypersensitivity reactions</p><p style="margin-right:-44.7pt">Angioneurotic oedema</p><p style="margin-right:-44.7pt">5. Gastro-intestinal diseases</p><p style="margin-right:-44.7pt">Ulcerative colitis</p><p style="margin-right:-44.7pt">Crohn&#39;s disease</p><p style="margin-right:-44.7pt">6. Respiratory diseases</p><p style="margin-right:-44.7pt">Fulminating or disseminated tuberculosis (with appropriate antituberculous chemotherapy)</p><p style="margin-right:-44.7pt">Aspiration of gastric contents</p><p style="margin-right:-44.7pt">7. Miscellaneous</p><p style="margin-right:-44.7pt">TB meningitis (with appropriate antituberculous chemotherapy)</p><p style="margin-right:-44.7pt"><strong><u>Intra-articular administration:</u></strong></p><p style="margin-right:-44.7pt">Rheumatoid arthritis</p><p style="margin-right:-44.7pt">Osteo-arthritis with an inflammatory component</p><p style="margin-right:-44.7pt"><strong><u>Soft tissue administration (intrabursal, periarticular, into tendon sheath):</u></strong></p><p style="margin-right:-44.7pt">Synovitis not associated with infection</p><p style="margin-right:-44.7pt">Epicondylitis</p><p style="margin-right:-44.7pt">Tenosynovitis</p><p style="margin-right:-44.7pt">Plantar fasciitis</p><p style="margin-right:-44.7pt">Bursitis</p><p style="margin-right:-44.7pt"><strong>Intralesional:</strong></p><p style="margin-right:-44.7pt">Keloids</p><p style="margin-right:-44.7pt">Localized lichen planus</p><p style="margin-right:-44.7pt">Localized lichen simplex</p><p style="margin-right:-44.7pt">Granuloma annulare</p><p style="margin-right:-44.7pt">Discoid lupus erythematosus</p><p style="margin-right:-44.7pt">Alopecia areata.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0cm; margin-right:-37.7pt">Epizolone Depot should not be mixed with any other suspending agent or solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever suspension and container permit. Epizolone Depot may be used by any of the following routes: intramuscular, intra-articular, periarticular, intrabursal, intralesional and into the tendon sheath. It must not be used by the intrathecal or intravenous routes (see Contra-indications and Undesirable effects).</p><p style="margin-left:0cm; margin-right:-37.7pt">Undesirable effects may be minimised by using the lowest effective dose for the minimum period (see Special warnings and special precautions for use).</p><p style="margin-left:0cm; margin-right:-37.7pt">Epizolone Depot vials are intended for single dose use only.</p><p style="margin-left:0cm; margin-right:-37.7pt">Intramuscular - for sustained systemic effect: Allergic conditions (severe seasonal and perennial allergic rhinitis, asthma, drug reactions), 80 - 120 mg (2 - 3 ml).</p><p style="margin-left:0cm; margin-right:-37.7pt">Dermatological conditions, 40 - 120 mg (1 - 3 ml).</p><p style="margin-left:0cm; margin-right:-37.7pt">Rheumatic disorders and collagen diseases (rheumatoid arthritis, SLE), 40 - 120 mg (1 - 3 ml) per week.</p><p style="margin-left:0cm; margin-right:-37.7pt">Dosage must be individualized and depends on the condition being treated and its severity.</p><p style="margin-left:0cm; margin-right:-37.7pt">Note: Epizolone Depot is not intended for the prophylaxis of severe seasonal and perennial allergic rhinitis or other seasonal allergies and should be administered only when symptoms are present.</p><p style="margin-left:0cm; margin-right:-37.7pt">The frequency of intramuscular injections should be determined by the duration of clinical response.</p><p style="margin-left:0cm; margin-right:-37.7pt">In the case of seasonal allergic rhinitis a single injection is frequently sufficient. If necessary, however, a second injection may be given after two to three weeks.</p><p style="margin-left:0cm; margin-right:-37.7pt">On average the effect of a single 2 ml (80 mg) injection may be expected to last approximately two weeks.</p><p style="margin-left:0cm; margin-right:-37.7pt">Intra-articular: Rheumatoid arthritis, osteo-arthritis. The dose of Epizolone Depot depends upon the size of the joint and the severity of the condition. Repeated injections, if needed, may be given at intervals of one to five or more weeks depending upon the degree of relief obtained from the initial injection. A suggested dosage guide is: large joint (knee, ankle, shoulder), 20 - 80 mg (0.5 - 2 ml); medium joint (elbow, wrist), 10 - 40 mg (0.25 - 1 ml); small joint (metacarpophalangeal, interphalangeal, sternoclavicular, acromioclavicular), 4 - 10 mg (0.1 - 0.25 ml).</p><p style="margin-left:0cm; margin-right:-37.7pt">Intrabursal: Subdeltoid bursitis, prepatellar bursitis, olecranon bursitis. For administration directly into bursae, 4 - 30 mg (0.1 - 0.75 ml). In most cases, repeat injections are not needed.</p><p style="margin-left:0cm; margin-right:-37.7pt">Intralesional: Keloids, localised lichen planus, localized lichen simplex, granuloma annulare, alopecia areata, and discoid lupus erythematosus. For administration directly into the lesion for local effect in dermatological conditions, 20 - 60 mg (0.5 - 1.5 ml). For large lesions, the dose may be distributed by repeated local injections of 20 - 40 mg (0.5 - 1 ml). One to four injections are usually employed. Care should be taken to avoid injection of sufficient material to cause blanching, since this may be followed by a small slough.</p><p style="margin-left:0cm; margin-right:-37.7pt">Peri-articular: Epicondylitis. Infiltrate 4 - 30 mg (0.1 - 0.75 ml) into the affected area.</p><p style="margin-left:0cm; margin-right:-37.7pt">Into the tendon sheath: Tenosynovitis, epicondylitis. For administration directly into the tendon sheath, 4 - 30 mg (0.1 - 0.75 ml). In recurrent or chronic conditions, repeat injections may be necessary.</p><p style="margin-left:0cm; margin-right:-37.7pt">Special precautions should be observed when administering Epizolone Depot. Intramuscular injections should be made deeply into the gluteal muscles. The usual technique of aspirating prior to injection should be employed to avoid intravascular administration. Doses recommended for intramuscular injection must not be administered superficially or subcutaneously.</p><p style="margin-left:0cm; margin-right:-37.7pt">Intra-articular injections should be made using precise, anatomical localisation into the synovial space of the joint involved. The injection site for each joint is determined by that location where the synovial cavity is most superficial and most free of large vessels and nerves. Suitable sites for intra-articular injection are the knee, ankle, wrist, elbow, shoulder, phalangeal and hip joints. The spinal joints, unstable joints and those devoid of synovial space are not suitable. Treatment failures are most frequently the result of failure to enter the joint space. Intra-articular injections should be made with care as follows: ensure correct positioning of the needle into the synovial space and aspirate a few drops of joint fluid. The aspirating syringe should then be replaced by another containing Epizolone Depot. To ensure position of the needle, synovial fluid should be aspirated and the injection made. After injection the joint is moved slightly to aid mixing of the synovial fluid and the suspension. Subsequent to therapy care should be taken for the patient not to overuse the joint in which benefit has been obtained. Negligence in this matter may permit an increase in joint deterioration that will more than offset the beneficial effects of the steroid.</p><p style="margin-left:0cm; margin-right:-37.7pt">Intrabursal injections should be made as follows: the area around the injection site is prepared in a sterile way and a wheal at the site made with 1 per cent procaine hydrochloride solution. A 20 to 24 gauge needle attached to a dry syringe is inserted into the bursa and the fluid aspirated. The needle is left in place and the aspirating syringe changed for a small syringe containing the desired dose. After injection, the needle is withdrawn and a small dressing applied. In the treatment of tenosynovitis care should be taken to inject Epizolone Depot into the tendon sheath rather than into the substance of the tendon. Due to the absence of a true tendon sheath, the Achilles tendon should not be injected with Epizolone Depot.</p><p style="margin-left:0cm; margin-right:-37.7pt"><strong>Children:</strong> Dosage may be reduced for infants and children but should be governed more by the severity of the condition and response of the patient, than by age or size.</p><p style="margin-left:0cm; margin-right:-37.7pt"><strong>Elderly patients:</strong> When used according to instructions, there is no information to suggest that a change in dosage is warranted in the elderly. However, treatment of elderly patients, particularly if long-term, should be planned bearing in mind the more serious consequences of the common side-effects of corticosteroids in old age and close clinical supervision is required (see Special warnings and special precautions for use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Epizolone Depot is contra-indicated in 
• in patients with known hypersensitivity to the active substance or to any of the excipients listed in section 6.1
• in patients who have systemic infection unless specific anti-infective therapy is employed
• for use by the intrathecal route (due to its potential for neurotoxicity)
• for use by the intravenous route (see section 4.8)
Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:-44.7pt"><strong>Warnings and Precautions:</strong></p><p style="margin-right:-44.7pt">Undesirable effects may be minimised by using the lowest effective dose for the minimum period. Frequent patient review is required to appropriately titrate the dose against disease activity (see section 4.2).</p><p style="margin-right:-44.7pt">Epizolone Depot vials are intended for single dose use only. Any multidose use of the product may lead to contamination.</p><p style="margin-right:-44.7pt">Severe medical events have been reported in association with the intrathecal/epidural routes of administration (see section 4.8). Appropriate measures must be taken to avoid intravascular injection.</p><p style="margin-right:-51.8pt">Due to the absence of a true tendon sheath, the Achilles tendon should not be injected with Epizolone Depot.</p><p style="margin-right:-44.7pt">While crystals of adrenal steroids in the dermis suppress inflammatory reactions, their presence may cause disintegration of the cellular elements and physiochemical changes in the ground substance of the connective tissue. The resultant infrequently occurring dermal and/or subdermal changes may form depressions in the skin at the injection site. The degree to which this reaction occurs will vary with the amount of adrenal steroid injected. Regeneration is usually complete within a few months or after all crystals of the adrenal steroid have been absorbed.</p><p style="margin-right:-44.7pt">In order to minimize the incidence of dermal and subdermal atrophy, care must be exercised not to exceed recommended doses in injections. Multiple small injections into the area of the lesion should be made whenever possible. The technique of intra-articular and intramuscular injection should include precautions against injection or leakage into the dermis. Injection into the deltoid muscle should be avoided because of a high incidence of subcutaneous atrophy.</p><p style="margin-right:-44.7pt">Intralesional doses should not be placed too superficially, particularly in easily visible sites in patients with deeply pigmented skins, since there have been rare reports of subcutaneous atrophy and depigmentation.</p><p style="margin-right:-44.7pt">Systemic absorption of methylprednisolone occurs following intra-articular injection of Epizolone Depot. Systemic as well as local effects can therefore be expected.</p><p style="margin-right:-44.7pt">Adrenal cortical atrophy develops during prolonged therapy and may persist for months after stopping treatment. In patients who have received more than physiological doses of systemic corticosteroids (approximately 6 mg methylprednisolone) for greater than 3 weeks, withdrawal should not be abrupt. How dose reduction should be carried out depends largely on whether the disease is likely to relapse as the dose of systemic corticosteroids is reduced. Clinical assessment of disease activity may be needed during withdrawal. If the disease is unlikely to relapse on withdrawal of systemic corticosteroids, but there is uncertainty about HPA suppression, the dose of systemic corticosteroid may be reduced rapidly to physiological doses. Once a daily dose of 6 mg methylprednisolone is reached, dose reduction should be slower to allow the HPA-axis to recover.</p><p style="margin-right:-44.7pt">The following precautions apply for parenteral corticosteroids:</p><p style="margin-right:-51.8pt">Following intra-articular injection, the occurrence of a marked increase in pain accompanied by local swelling, further restriction of joint motion, fever, and malaise are suggestive of septic arthritis. If this complication occurs and the diagnosis of sepsis is confirmed, appropriate antimicrobial therapy should be instituted.</p><p style="margin-right:-44.7pt">Local injection of a steroid into a previously infected joint is to be avoided.</p><p style="margin-right:-44.7pt">Intra-articular corticosteroids are associated with a substantially increased risk of inflammatory response in the joint, particularly bacterial infection introduced with the injection. Charcot-like arthropathies have been reported particularly after repeated injections. Appropriate examination of any joint fluid present is necessary to exclude any bacterial infection, prior to injection.</p><p style="margin-right:-44.7pt">Corticosteroids should not be injected into unstable joints.</p><p style="margin-right:-44.7pt">Sterile technique is necessary to prevent infections or contamination.</p><p style="margin-right:-44.7pt">The slower rate of absorption by intramuscular administration should be recognised.</p><p style="margin-right:-44.7pt"><strong>Immunosuppressant Effects/Increased Susceptibility to Infections</strong></p><p style="margin-right:-44.7pt">Corticosteroids may increase susceptibility to infection, may mask some signs of infection, and new infections may appear during their use. Suppression of the inflammatory response and immune function increases the susceptibility to fungal, viral and bacterial infections and their severity. The clinical presentation may often be atypical and may reach an advanced stage before being recognised. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases.</p><p style="margin-right:-44.7pt">Do not use intra-synovially, intrabursally or intratendinous administration for local effect in the presence of acute infection.</p><p style="margin-right:-44.7pt">Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids.</p><p style="margin-right:-44.7pt">Chickenpox is of serious concern since this normally minor illness may be fatal in immunosuppressed patients. Patients (or parents of children) without a definite history of chickenpox should be advised to avoid close personal contact with chickenpox or herpes zoster and if exposed they should seek urgent medical attention. Passive immunization with varicella/zoster immunoglobin (VZIG) is needed by exposed non-immune patients who are receiving systemic corticosteroids or who have used them within the previous 3 months; this should be given within 10 days of exposure to chickenpox. If a diagnosis of chickenpox is confirmed, the illness warrants specialist care and urgent treatment.</p><p style="margin-right:-44.7pt">Corticosteroids should not be stopped and the dose may need to be increased.</p><p style="margin-right:-44.7pt">Live vaccines should not be given to individuals with impaired immune responsiveness. The antibody response to other vaccines may be diminished.</p><p style="margin-right:-44.7pt">The use of Epizolone Depot in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen. If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.</p><p style="margin-right:-44.7pt">The role of corticosteroids in septic shock has been controversial, with early studies reporting both beneficial and detrimental effects. More recently, supplemental corticosteroids have been suggested to be beneficial in patients with established septic shock who exhibit adrenal insufficiency. However, their routine use in septic shock is not recommended. A systematic review of short-course high-dose corticosteroids did not support their use. However, meta-analyses and a review suggest that longer courses (5-11 days) of low-dose corticosteroids might reduce mortality, especially in patients with vasopressor-dependent septic shock.</p><p style="margin-right:-44.7pt"><strong>Immune System Effects</strong></p><p style="margin-right:-44.7pt">Allergic reactions may occur. Because rare instances of skin reactions and anaphylactic/anaphylactoid reactions have occurred in patients receiving corticosteroid therapy, appropriate precautionary measures should be taken prior to administration, especially when the patient has a history of drug allergy.</p><p style="margin-right:-44.7pt"><strong>Endocrine Effects</strong></p><p style="margin-right:-44.7pt">Pharmacologic doses of corticosteroids administered for prolonged periods may result in hypothalamic-pituitary-adrenal (HPA) suppression (secondary adrenocortical insufficiency). The degree and duration of adrenocortical insufficiency produced is variable among patients and depends on the dose, frequency, time of administration, and duration of glucocorticoid therapy. This effect may be minimized by use of alternate-day therapy.</p><p style="margin-right:-44.7pt">In addition, acute adrenal insufficiency leading to a fatal outcome may occur if glucocorticoids are withdrawn abruptly.</p><p style="margin-right:-44.7pt">Drug-induced secondary adrenocortical insufficiency may therefore be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Salt and/or a mineralocorticoid are only needed if mineralocorticoid secretion is impaired.</p><p style="margin-right:-44.7pt">A steroid &ldquo;withdrawal syndrome,&rdquo; seemingly unrelated to adrenocortical insufficiency, may also occur following abrupt discontinuance of glucocorticoids. This syndrome includes symptoms such as: anorexia, nausea, vomiting, lethargy, headache, fever, joint pain, desquamation, myalgia, weight loss, and/or hypotension. These effects are thought to be due to the sudden change in glucocorticoid concentration rather than to low corticosteroid levels.</p><p style="margin-right:-44.7pt">Abrupt withdrawal of systemic corticosteroid treatment, which has continued up to 3 weeks is appropriate if it considered that the disease is unlikely to relapse. Abrupt withdrawal of doses up to 32 mg daily of methylprednisolone for 3 weeks is unlikely to lead to clinically relevant HPA-axis suppression, in the majority of patients. In the following patient groups, gradual withdrawal of systemic corticosteroid therapy should be considered even after courses lasting 3 weeks or less:</p><p style="margin-right:-44.7pt">&bull; Patients who have had repeated courses of systemic corticosteroids, particularly if taken for greater than 3 weeks.</p><p style="margin-right:-44.7pt">&bull; When a short course has been prescribed within one year of cessation of long-term therapy (months or years).</p><p style="margin-right:-44.7pt">&bull; Patients who may have reasons for adrenocortical insufficiency other than exogenous corticosteroid therapy.</p><p style="margin-right:-44.7pt">&bull; Patients receiving doses of systemic corticosteroid greater than 32 mg daily of methylprednisolone.</p><p style="margin-right:-44.7pt">&bull; Patients repeatedly taking doses in the evening.</p><p style="margin-right:-44.7pt">Because glucocorticoids can produce or aggravate Cushing&#39;s syndrome, glucocorticoids should be avoided in patients with Cushing&#39;s disease.</p><p style="margin-right:-44.7pt">There is an enhanced effect of corticosteroids on patients with hypothyroidism.</p><p style="margin-right:-44.7pt"><strong>Metabolism and Nutrition</strong></p><p style="margin-right:-44.7pt">Corticosteroids, including methylprednisolone, can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term corticosteroid therapy to diabetes mellitus.</p><p style="margin-right:-44.7pt"><strong>Psychiatric Effects</strong></p><p style="margin-right:-44.7pt">Patients and/or carers should be warned that potentially severe psychiatric adverse reactions may occur with systemic steroids (see section 4.8). Symptoms typically emerge within a few days or weeks of starting treatment. Risks may be higher with high doses/systemic exposure (see section 4.5), although dose levels do not allow prediction of the onset, type, severity or duration of reactions. Most reactions recover after either dose reduction or withdrawal, although specific treatment may be necessary. Patients/carers should be encouraged to seek medical advice if worrying psychological symptoms develop, especially if depressed mood or suicidal ideation is suspected. Patients/carers should be alert to possible psychiatric disturbances that may occur either during or immediately after dose tapering/withdrawal of systemic steroids, although such reactions have been reported infrequently.</p><p style="margin-right:-44.7pt">Particular care is required when considering the use of systemic corticosteroids in patients with existing or previous history of severe affective disorders in themselves or in their first degree relatives. These would include depressive or manic-depressive illness and previous steroid psychosis.</p><p style="margin-right:-44.7pt"><strong>Nervous System Effects</strong></p><p style="margin-right:-44.7pt">Corticosteroids should be used with caution in patients with seizure disorders.</p><p style="margin-right:-44.7pt">Corticosteroids should be used with caution in patients with myasthenia gravis (Also see myopathy statement in Musculoskeletal Effects section).</p><p style="margin-right:-44.7pt">There have been reports of epidural lipomatosis in patients taking corticosteroids, typically with long-term use at high doses.</p><p style="margin-right:-44.7pt"><strong>Ocular Effects</strong></p><p style="margin-right:-44.7pt">Prolonged use of corticosteroids may produce posterior subcapsular cataracts and nuclear cataracts (particularly in children), exophthalmos, or increased intraocular pressure, which may result in glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.</p><p style="margin-right:-44.7pt">Corticosteroids should be used cautiously in patients with ocular herpes simplex, because of possible corneal perforation.</p><p style="margin-right:-44.7pt">Corticosteroid therapy has been associated with central serous chorioretinopathy, which may lead to retinal detachment.</p><p style="margin-right:-44.7pt"><strong>Cardiac Effects</strong></p><p style="margin-right:-44.7pt">Adverse effects of glucocorticoids on the cardiovascular system, such as dyslipidaemia and hypertension, may predispose treated patients with existing cardiovascular risk factors to additional cardiovascular effects, if high doses and prolonged courses are used. Accordingly, corticosteroids should be employed judiciously in such patients and attention should be paid to risk modification and additional cardiac monitoring if needed.</p><p style="margin-right:-44.7pt">Systemic corticosteroids should be used with caution, and only if strictly necessary, in cases of congestive heart failure.</p><p style="margin-right:-44.7pt"><strong>Vascular Effects</strong></p><p style="margin-right:-44.7pt">Corticosteroids should be used with caution in patients with hypertension.</p><p style="margin-right:-44.7pt">Thrombosis including venous thromboembolism has been reported to occur with corticosteroids. As a result corticosteroids should be used with caution in patients who have or may be predisposed to thromboembolic disorders.</p><p style="margin-right:-44.7pt"><strong>Gastrointestinal Effects</strong></p><p style="margin-right:-44.7pt">There is no universal agreement on whether corticosteroids per se are responsible for peptic ulcers encountered during therapy; however, glucocorticoid therapy may mask the symptoms of peptic ulcer so that perforation or haemorrhage may occur without significant pain. In combination with NSAIDs, the risk of developing gastrointestinal ulcers is increased.</p><p style="margin-right:-51.8pt">Corticosteroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection. Caution must also be used in diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, when steroids are used as direct or adjunctive therapy.</p><p style="margin-right:-44.7pt"><strong>Hepatobiliary Effects</strong></p><p style="margin-right:-44.7pt">Drug induced liver injury including acute hepatitis or liver enzyme increase can result from cyclical pulsed IV methylprednisolone (usually at initial dose &gt; 1 g / day). Rare cases of hepatotoxicity have been reported. The time to onset can be several weeks or longer. In the majority of case reports resolution of the adverse events has been observed after treatment was discontinued. Therefore, appropriate monitoring is required.</p><p style="margin-right:-44.7pt">High doses of corticosteroids may produce acute pancreatitis.</p><p style="margin-right:-44.7pt">Corticosteroids should be used with caution in patients with liver failure or cirrhosis.</p><p style="margin-right:-44.7pt"><strong>Musculoskeletal Effects</strong></p><p style="margin-right:-44.7pt">An acute myopathy has been reported with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., myasthenia gravis), or in patients receiving concomitant therapy with anticholinergics, such as neuromuscular blocking drugs (e.g., pancuronium). This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Elevations of creatine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.</p><p style="margin-right:-44.7pt">Osteoporosis is a common but infrequently recognized adverse effect associated with a long-term use of large doses of glucocorticoid.</p><p style="margin-right:-44.7pt"><strong>Renal and Urinary Disorders</strong></p><p style="margin-right:-44.7pt">Corticosteroids should be used with caution in patients with renal insufficiency.</p><p style="margin-right:-44.7pt"><strong>Investigations</strong></p><p style="margin-right:-44.7pt">Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.</p><p style="margin-right:-44.7pt">Care should be taken for patients receiving cardio active drugs such as digoxin because of steroid induced electrolyte disturbance/potassium loss (see section 4.8).</p><p style="margin-right:-44.7pt"><strong>Injury, Poisoning and Procedural Complications</strong></p><p style="margin-right:-44.7pt">Systemic corticosteroids are not indicated for, and therefore should not be used to treat, traumatic brain injury, a multicenter study revealed an increased mortality at 2 weeks and 6 months after injury in patients administered methylprednisolone sodium succinate compared to placebo. A causal association with methylprednisolone sodium succinate treatment has not been established.</p><p style="margin-right:-44.7pt"><strong>Other</strong></p><p style="margin-right:-44.7pt">Patients should carry &#39;Steroid Treatment&#39; cards which give clear guidance on the precautions to be taken to minimise risk and which provide details of prescriber, drug, dosage and the duration of treatment. Corticosteroids should be used with caution in patients with a predisposition to thrombophlebitis.</p><p style="margin-right:-44.7pt">Aspirin and nonsteroidal anti-inflammatory agents should be used cautiously in conjunction with corticosteroids.</p><p style="margin-right:-44.7pt">Pheochromocytoma crisis, which can be fatal, has been reported after administration of systemic corticosteroids.</p><p style="margin-right:-51.8pt">Corticosteroids should only be administered to patients with suspected or identified pheochromocytoma after an appropriate risk/benefit evaluation.</p><p style="margin-right:-44.7pt"><strong>Paediatric population</strong></p><p style="margin-right:-44.7pt">Corticosteroids cause growth retardation in infancy, childhood and adolescence which may be irreversible. Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed. Treatment should be limited to the minimum dosage for the shortest possible time. The use of such a regimen should be restricted to those most serious indications.</p><p style="margin-right:-51.8pt">Infants and children on prolonged corticosteroid therapy are at special risk from raised intracranial pressure.</p><p style="margin-right:-44.7pt">High doses of corticosteroids may produce pancreatitis in children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:-44.7pt">Methylprednisolone is a cytochrome P450 enzyme (CYP) substrate and is mainly metabolized by the CYP3A enzyme. CYP3A4 is the dominant enzyme of the most abundant CYP subfamily in the liver of adult humans. It catalyzes 6<strong>&beta;</strong>-hydroxylation of steroids, the essential Phase I metabolic step for both endogenous and synthetic corticosteroids.</p><p style="margin-right:-44.7pt">Many other compounds are also substrates of CYP3A4, some of which (as well as other drugs) have been shown to alter glucocorticoid metabolism by induction (upregulation) or inhibition of the CYP3A4 enzyme.</p><p style="margin-right:-44.7pt">CYP3A4 INHIBITORS &ndash; Drugs that inhibit CYP3A4 activity generally decrease hepatic clearance and increase the plasma concentration of CYP3A4 substrate medications, such as methylprednisolone. In the presence of a CYP3A4 inhibitor, the dose of methylprednisolone may need to be titrated to avoid steroid toxicity.</p><p style="margin-right:-44.7pt">CYP3A4 INDUCERS &ndash; Drugs that induce CYP3A4 activity generally increase hepatic clearance, resulting in decreased plasma concentration of medications that are substrates for CYP3A4. Coadministration may require an increase in methylprednisolone dosage to achieve the desired result.</p><p style="margin-right:-44.7pt">CYP3A4 SUBSTRATES &ndash; In the presence of another CYP3A4 substrate, the hepatic clearance of methylprednisolone may be affected, with corresponding dosage adjustments required. It is possible that adverse events associated with the use of either drug alone may be more likely to occur with coadministration.</p><p style="margin-right:-51.8pt">1. Convulsions have been reported with concurrent use of methylprednisolone and ciclosporin (CYP3A4 inhibitor and substrate). Since concurrent administration of these agents results in a mutual inhibition of metabolism (which may increase the plasma concentrations of either or both drugs), it is possible that convulsions and other adverse effects associated with the individual use of either drug may be more apt to occur.</p><p style="margin-right:-44.7pt">2. Drugs that induce hepatic enzymes, such as rifampicin (antibiotic CYP3A4 inducer), rifabutin, carbamazepine (anticonvulsant CYP3A4 inducer and substrate), phenobarbitone and phenytoin (anticonvulsants CYP3A4 inducers), primidone, and aminoglutethimide (aromatase inhibitor) enhance the metabolism of corticosteroids and its therapeutic effects may be reduced. Aminoglutethimide- induced adrenal suppression may exacerbate endocrine changes caused by prolonged glucocorticoid treatment.</p><p style="margin-right:-44.7pt">The acetylation rate and clearance of isoniazid (CYP3A4 inhibitor), an antibacterial drug, can be increased by methylprednisolone.</p><p style="margin-right:-44.7pt">3. Antibiotics/Antimycotics - Drugs such as erythromycin (macrolide antibacterial CYP3A4 inhibitor and substrate), itraconazole and ketoconazole (antifungal CYP3A4 inhibitors and substrates) may inhibit the metabolism of corticosteroids and thus decrease their clearance.</p><p style="margin-right:-44.7pt">Troleandomycin (CYP3A4 inhibitor), as well as clarithromycin, erythromycin, itraconazole and ketoconazole (CYP3A4 inhibitors and substrates) increase the effects and the side effects of methylprednisolone.</p><p style="margin-right:-44.7pt">4. Steroids may reduce the effects of anticholinesterases in myasthenia gravis. The desired effects of hypoglycaemic agents (including insulin), anti-hypertensives and diuretics are antagonised by corticosteroids, and the hypokalaemic effects of acetazolamide, loop diuretics, thiazide diuretics and carbenoxolone are enhanced.</p><p style="margin-right:-44.7pt">An acute myopathy has been reported with the concomitant use of high doses of corticosteroids and anticholinergics, such as neuromuscular blocking drugs. (see section 4.4).</p><p style="margin-right:-44.7pt">Antagonism of the neuromuscular blocking effects of pancuronium and vecuronium has been reported in patients taking corticosteroids. This interaction may be expected with all competitive neuromuscular blockers.</p><p style="margin-right:-44.7pt">5. The effect of methylprednisolone on oral anticoagulants is variable. The efficacy of coumarin anticoagulants may be enhanced by concurrent corticosteroid therapy and close monitoring of the INR or prothrombin time is required to avoid spontaneous bleeding and to maintain the desired anticoagulant effects.</p><p style="margin-right:-44.7pt">There are also reports of diminished effects of anticoagulants when given concurrently with corticosteroids.</p><p style="margin-right:-44.7pt">6. There may be increased incidence of gastrointestinal bleeding and ulceration when corticosteroids are given with NSAIDs.</p><p style="margin-right:-44.7pt">Methylprednisolone may increase the clearance of high-dose aspirin, which can lead to decreased salicylate serum levels. Discontinuation of methylprednisolone treatment can lead to raised salicylate serum levels, which could lead to an increased risk of salicylate toxicity. Salicylates and non-steroidal anti-inflammatory agents should be used cautiously in conjunction with corticosteroids in hypothrombinaemia.</p><p style="margin-right:-44.7pt">7. Antidiabetics- Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.</p><p style="margin-right:-44.7pt">8. Antiemetics - Aprepitant and fosaprepitant (CYP3A4 inhibitors and substrates)</p><p style="margin-right:-44.7pt">9. Antivirals - HIV protease inhibitors:</p><p style="margin-right:-44.7pt">1) Indinavir and ritonavir (CYP3A4 inhibitors and substrates) may increase plasma concentrations of corticosteroids.</p><p style="margin-right:-44.7pt">2) Corticosteroids may induce the metabolism of HIV-protease inhibitors resulting in reduced plasma concentrations.</p><p style="margin-right:-44.7pt">10. Calcium channel blocker - Diltiazem (CYP3A4 inhibitor and substrate).</p><p style="margin-right:-44.7pt">11. Contraceptives (oral) - Ethinylestradiol/norethindrone (CYP3A4 inhibitors and substrate).</p><p style="margin-right:-44.7pt">12. Other immunosuppressants like cyclophosphamide and tacrolimus are substrates of CYP3A4.</p><p style="margin-right:-44.7pt">13. Potassium-depleting agents -When corticosteroids are administered concomitantly with potassium-depleting agents (e.g. diuretics), patients should be observed closely for development of hypokalaemia. There is also an increased risk of hypokalaemia with concurrent use of corticosteroids with amphotericin B, xanthenes, or beta2 agonists.</p><p style="margin-right:-44.7pt">14. Grapefruit juice &ndash; CYP3A4 inhibitor.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0cm; margin-right:-44.8pt"><strong>Fertility</strong></p><p style="margin-left:0cm; margin-right:-44.8pt">There is no evidence that corticosteroids impair fertility (see section 5.3).</p><p style="margin-left:0cm; margin-right:-44.8pt"><strong>Pregnancy</strong></p><p style="margin-left:0cm; margin-right:-44.8pt">The ability of corticosteroids to cross the placenta varies between individual drugs, however, methylprednisolone does cross the placenta. One retrospective study found an increased incidence of low birth weights in infants born of mothers receiving corticosteroids.</p><p style="margin-left:0cm; margin-right:-44.8pt">Administration of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate, intra-uterine growth retardation and affects on brain growth and development. There is no evidence that corticosteroids result in an increased incidence of congenital abnormalities, such as cleft palate in man, however, when administered for long periods or repeatedly during pregnancy, corticosteroids may increase the risk of intra-uterine growth retardation. Hypoadrenalism may, in theory, occur in the neonate following prenatal exposure to corticosteroids but usually resolves spontaneously following birth and is rarely clinically important. Although neonatal adrenal insufficiency appears to be rare in infants who were exposed in utero to corticosteroids, those exposed to substantial doses of corticosteroids must be carefully observed and evaluated for signs of adrenal insufficiency. As with all drugs, corticosteroids should only be prescribed when the benefits to the mother and child outweigh the risks. When corticosteroids are essential, however, patients with normal pregnancies may be treated as though they were in the non-gravid state.</p><p style="margin-left:0cm; margin-right:-44.8pt">Cataracts have been observed in infants born to mothers treated with long-term corticosteroids during pregnancy.</p><p style="margin-left:0cm; margin-right:-44.8pt"><strong>Breast-feeding</strong></p><p style="margin-left:0cm; margin-right:-44.8pt">Corticosteroids are excreted in small amounts in breast milk, however, doses of up to 40 mg daily of methylprednisolone are unlikely to cause systemic effects in the infant. Infants of mothers taking higher doses than this may have a degree of adrenal suppression, but the benefits of breast-feeding are likely to outweigh any theoretical risk.</p><p style="margin-left:0cm; margin-right:-44.8pt">Corticosteroids distributed into breast milk may interfere with endogenous glucocorticoid production in nursing infants.</p><p style="margin-left:0cm; margin-right:-44.8pt">Since adequate reproductive studies have not been performed in humans with glucocorticoids, these drugs should be administered to nursing mothers only if the benefits of therapy are judged to outweigh the potential risks to the infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0cm; margin-right:-25.55pt">The effect of corticosteroids on the ability to drive or use machinery has not been systematically evaluated. Undesirable effects, such as dizziness, vertigo, visual disturbances, and fatigue are possible after treatment with corticosteroids. If affected, patients should not drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0cm; margin-right:-37.6pt">The incidence of predictable undesirable side effects associated with the use of corticosteroids, including hypothalamicpituitary-adrenal suppression correlates with the relative potency of the drug, dosage, timing of administration and duration of treatment (see section 4.4).</p><table border="1" cellspacing="0" cellpadding="0" style="width:501.55pt"><thead><tr><td style="background-color:#d9d9d9; width:133.0pt"><p style="text-align:center"><strong>MedDRA</strong></p><p style="text-align:center"><strong>System Organ Class</strong></p></td><td style="background-color:#d9d9d9; width:70.85pt"><p style="text-align:center"><strong>Frequency</strong></p></td><td style="background-color:#d9d9d9; width:297.7pt"><p style="text-align:center"><strong>Undesirable Effects</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top; width:133.0pt"><p>Infections and infestations</p></td><td style="vertical-align:top; width:70.85pt"><p>Not Known</p></td><td style="vertical-align:top; width:297.7pt"><p>Infection (including increased susceptibility and severity of infections with suppression of clinical symptoms and signs); Opportunistic infection; Injection site infection;</p><p>Peritonitis; Recurrence of dormant tuberculosis</p></td></tr><tr><td style="vertical-align:top; width:133.0pt"><p style="margin-right:-5.2pt">Immune system disorders</p></td><td style="vertical-align:top; width:70.85pt"><p>Not Known</p></td><td style="vertical-align:top; width:297.7pt"><p>Drug hypersensitivity, Anaphylactic reaction</p></td></tr><tr><td style="height:12.05pt; vertical-align:top; width:133.0pt"><p>Blood and lymphatic system disorders</p></td><td style="height:12.05pt; vertical-align:top; width:70.85pt"><p>Not Known</p></td><td style="height:12.05pt; vertical-align:top; width:297.7pt"><p>Leukocytosis</p></td></tr><tr><td style="height:12.05pt; vertical-align:top; width:133.0pt"><p>Endocrine disorders</p></td><td style="height:12.05pt; vertical-align:top; width:70.85pt"><p>Not Known</p></td><td style="height:12.05pt; vertical-align:top; width:297.7pt"><p>Cushingoid; Hypopituitarism; Withdrawal symptoms - Too rapid a reduction of corticosteroid dosage following prolonged treatment can lead to acute adrenal insufficiency, hypotension and death. However, this is more applicable to corticosteroids with an indication where continuous therapy is given (see section 4.4).</p><p>A &#39;withdrawal syndrome&#39; may also occur including, fever, myalgia, arthralgia, rhinitis, conjunctivitis, painful itchy skin nodules and loss of weight.</p></td></tr><tr><td style="height:12.05pt; vertical-align:top; width:133.0pt"><p>Metabolism and nutrition disorders</p></td><td style="height:12.05pt; vertical-align:top; width:70.85pt"><p>Not Known</p></td><td style="height:12.05pt; vertical-align:top; width:297.7pt"><p>Glucose tolerance impaired; Sodium retention; Fluid retention; Increased requirements for insulin (or oral hypoglycemic agents in diabetics)[not a MedDRA PT]; Alkalosis hypokalaemic; Dyslipidaemia, Increased appetite (which may result in Weight increased); Epidural lipomatosis</p></td></tr><tr><td style="height:12.05pt; vertical-align:top; width:133.0pt"><p>Psychiatric disorders</p></td><td style="height:12.05pt; vertical-align:top; width:70.85pt"><p>Not Known</p></td><td style="height:12.05pt; vertical-align:top; width:297.7pt"><p>Affective disorder (including Depressed mood, Euphoric mood, Affect lability, Drug dependence, Suicidal ideation). The following events were most common in children: Mood swings; Abnormal behaviour; Insomnia; Psychotic disorder (including Mania, Delusion, Hallucination, and Schizophrenia [aggravation of]); Confusional state; Mental disorder; Anxiety; Personality change; Mood swings; Abnormal behaviour; Insomnia</p></td></tr><tr><td style="height:12.05pt; vertical-align:top; width:133.0pt"><p>Nervous system disorders</p></td><td style="height:12.05pt; vertical-align:top; width:70.85pt"><p>Not Known</p></td><td style="height:12.05pt; vertical-align:top; width:297.7pt"><p>Intracranial pressure increased (with Papilloedema [Benign intracranial hypertension]); Convulsion; Amnesia; Cognitive disorder; Dizziness; Headache; Epidural lipomatosis</p></td></tr><tr><td style="height:12.05pt; vertical-align:top; width:133.0pt"><p>Eye disorders</p></td><td style="height:12.05pt; vertical-align:top; width:70.85pt"><p>Not Known</p></td><td style="height:12.05pt; vertical-align:top; width:297.7pt"><p>Cataract; Glaucoma; Exophthalmos; Chorioretinopathy; rare instances of blindness associated with intralesional therapy around the face and head [not a MedDRA PT]; Increased intra-ocular pressure, with possible damage to the optic nerve; Corneal or scleral thinning; Exacerbation of ophthalmic viral or fungal disease</p></td></tr><tr><td style="height:12.05pt; vertical-align:top; width:133.0pt"><p>Ear and labyrinth disorders</p></td><td style="height:12.05pt; vertical-align:top; width:70.85pt"><p>Not Known</p></td><td style="height:12.05pt; vertical-align:top; width:297.7pt"><p>Vertigo</p></td></tr><tr><td style="height:12.05pt; vertical-align:top; width:133.0pt"><p>Cardiac disorders</p></td><td style="height:12.05pt; vertical-align:top; width:70.85pt"><p>Not Known</p></td><td style="height:12.05pt; vertical-align:top; width:297.7pt"><p>Cardiac failure congestive (in susceptible patients)</p></td></tr><tr><td style="height:12.05pt; vertical-align:top; width:133.0pt"><p>Vascular disorders</p></td><td style="height:12.05pt; vertical-align:top; width:70.85pt"><p>Not Known</p></td><td style="height:12.05pt; vertical-align:top; width:297.7pt"><p>Hypertension; Hypotension; Embolism arterial, Thrombotic events</p></td></tr><tr><td style="height:19.05pt; vertical-align:top; width:133.0pt"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="height:19.05pt; vertical-align:top; width:70.85pt"><p>Not Known</p></td><td style="height:19.05pt; vertical-align:top; width:297.7pt"><p>Pulmonary embolism, Hiccups</p></td></tr><tr><td style="height:51.9pt; vertical-align:top; width:133.0pt"><p>Gastrointestinal disorders</p></td><td style="height:51.9pt; vertical-align:top; width:70.85pt"><p>Not Known</p></td><td style="height:51.9pt; vertical-align:top; width:297.7pt"><p>Peptic ulcer (with possible Peptic ulcer perforation and Peptic ulcer haemorrhage); Gastric haemorrhage; Intestinal perforation; Pancreatitis; Oesophagitis ulcerative; Oesophagitis; Abdominal pain; Abdominal distension; Diarrhoea; Dyspepsia; Nausea</p></td></tr><tr><td style="height:7.55pt; vertical-align:top; width:133.0pt"><p>Hepatobiliary disorders</p></td><td style="height:7.55pt; vertical-align:top; width:70.85pt"><p>Not known</p></td><td style="height:7.55pt; vertical-align:top; width:297.7pt"><p>Hepatitis, Increase of liver enzymes</p></td></tr><tr><td style="height:14.1pt; vertical-align:top; width:133.0pt"><p>Skin and subcutaneous tissue disorders</p></td><td style="height:14.1pt; vertical-align:top; width:70.85pt"><p>Not Known</p></td><td style="height:14.1pt; vertical-align:top; width:297.7pt"><p>Ecchymosis; Acne; Angioedema; Petechiae; Skin atrophy; Skin striae; Skin hyperpigmentation; Skin hypopigmentation; Hirsutism; Rash; Erythema; Pruritus; Urticaria; Hyperhidrosis</p></td></tr><tr><td style="height:19.05pt; vertical-align:top; width:133.0pt"><p>Musculoskeletal and connective tissue disorders</p></td><td style="height:19.05pt; vertical-align:top; width:70.85pt"><p style="text-align:center">Not Known</p></td><td style="height:19.05pt; vertical-align:top; width:297.7pt"><p>Growth retardation; Osteoporosis; Muscular weakness;</p><p>Osteonecrosis; Pathological fracture; Muscle atrophy;</p><p>Myopathy; Neuropathic arthropathy; Arthralgia; Myalgia</p></td></tr><tr><td style="height:19.05pt; vertical-align:top; width:133.0pt"><p>Reproductive system and breast disorders</p></td><td style="height:19.05pt; vertical-align:top; width:70.85pt"><p style="text-align:center">Not Known</p></td><td style="height:19.05pt; vertical-align:top; width:297.7pt"><p>Menstruation irregular</p></td></tr><tr><td style="height:37.3pt; vertical-align:top; width:133.0pt"><p>General disorders and administration site conditions</p></td><td style="height:37.3pt; vertical-align:top; width:70.85pt"><p style="text-align:center">Not Known</p></td><td style="height:37.3pt; vertical-align:top; width:297.7pt"><p>Impaired healing; Oedema peripheral; Irritability (in children); Injection site reaction; Abscess sterile; Fatigue; Malaise; Irritability (in adults)</p></td></tr><tr><td style="height:19.05pt; vertical-align:top; width:133.0pt"><p>Investigations</p></td><td style="height:19.05pt; vertical-align:top; width:70.85pt"><p style="text-align:center">Not Known</p></td><td style="height:19.05pt; vertical-align:top; width:297.7pt"><p>Blood potassium decreased; Alanine aminotransferase increased; Aspartate aminotransferase increased; Blood alkaline phosphatase increased; Carbohydrate tolerance decreased; Urine calcium increased; suppression of reactions to skin tests [not a MedDRAPT]; Blood urea increased; Nitrogen balance negative (due to protein catabolism)</p></td></tr><tr><td style="height:19.05pt; vertical-align:top; width:133.0pt"><p>Injury, poisoning and</p><p>procedural complications</p></td><td style="height:19.05pt; vertical-align:top; width:70.85pt"><p style="text-align:center">Not Known</p></td><td style="height:19.05pt; vertical-align:top; width:297.7pt"><p>Tendon rupture (particularly of the Achilles tendon); Spinal compression fracture. Systemic corticosteroids are not indicated for, and therefore should not be used to treat, traumatic brain injury.</p></td></tr></tbody></table><p style="margin-left:0cm; margin-right:-37.7pt">&nbsp;</p><p style="margin-left:0cm; margin-right:-37.7pt">Common (&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to &lt;1/1,000); Not known (frequency cannot be estimated from the available data).</p><p style="margin-left:0cm; margin-right:-37.7pt"><strong><u>CERTAIN SIDE EFFECTS REPORTED WITH SOME CONTRAINDICATED AND NON-RECOMMENDED ROUTES OF ADMINISTRATION.</u></strong></p><p style="margin-left:0cm; margin-right:-37.7pt">Intrathecal/Epidural: Usual systemic corticoid adverse reactions, headache, meningismus, meningitis, paraparesis/paraplegia, spinal fluid abnormalities, nausea, vomiting, sweating, arachnoiditis, functional gastrointestinal disorder/bladder dysfunction, convulsions, sensory disturbances. The frequency of these adverse reactions is not known.</p><p style="margin-left:0cm; margin-right:-37.7pt">Extradural: Wound dehiscence, loss of sphincter control.</p><p style="margin-left:0cm; margin-right:-37.7pt">Intranasal: Permanent/temporary blindness, rhinitis.</p><p style="margin-left:0cm; margin-right:-37.7pt">Ophthalmic: (Subconjunctival) - Redness and itching, abscess, slough at injection site, residue at injection site, increased intra-ocular pressure, decreased vision - blindness, infection.</p><p style="margin-left:0cm; margin-right:-37.7pt">Miscellaneous injection sites - Scalp, tonsillar fauces, sphenopalatine ganglion: blindness.</p><p style="margin-left:0cm; margin-right:-37.7pt">To report any side effects:</p><p style="margin-left:0cm; margin-right:-37.7pt">&bull; Saudi Arabia:</p><p style="margin-left:0cm; margin-right:-37.7pt">The National Pharmacovigilance and Drug Safety Centre NPC</p><p style="margin-left:0cm; margin-right:-37.7pt">Fax: +966‐11‐205‐7662</p><p style="margin-left:0cm; margin-right:-37.7pt">Call NPC at +966‐11‐2038222, Exts 2317‐2356‐2353‐2354‐2334‐2340.</p><p style="margin-left:0cm; margin-right:-37.7pt">Toll free phone: 8002490000</p><p style="margin-left:0cm; margin-right:-37.7pt">E‐mail: npc.drug@sfda.gov.sa</p><p style="margin-left:0cm; margin-right:-37.7pt">Website: www.sfda.gov.sa/npc</p><p style="margin-left:0cm; margin-right:-37.7pt"><strong>Or Other GCC States:</strong></p><p style="margin-left:0cm; margin-right:-37.7pt">Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:-44.7pt">Following overdosage the possibility of adrenal suppression should be guarded against by gradual diminution of dose levels over a period of time. In such event the patient may require to be supported during any further traumatic episode.</p><p style="margin-right:-44.7pt">Reports of acute toxicity and/or death following overdosage of corticosteroids are rare. In the event of overdosage, no specific antidote is available; treatment is supportive and symptomatic. Methylprednisolone is dialysable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:-44.7pt">Pharmacotherapeutic group: Glucocorticoids, ATC code: H02AB04</p><p style="margin-right:-44.7pt">&nbsp;Methylprednisolone acetate is a synthetic glucocorticoid. It has greater anti-inflammatory potency than prednisolone and less tendency than prednisolone to induce sodium and water retention. An aqueous suspension may be injected directly into joints and soft tissues in the treatment of rheumatoid arthritis, osteoarthritis, bursitis and similar inflammatory conditions. For prolonged systemic effect it may be administered intramuscularly.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:-44.7pt"><strong><u>Absorption:</u></strong></p><p style="margin-right:-44.7pt">One in-house study of eight volunteers determined the pharmacokinetics of a single 40 mg intramuscular dose of Epizolone Depot. The average of the individual peak plasma concentrations was 14.8 &plusmn; 8.6 ng/mL, the average of the individual peak times was 7.25 &plusmn; 1.04 hours, and the average area under the curve (AUC) was 1354.2 &plusmn; 424.1 ng/mL xhrs (Day 1-21).</p><p style="margin-right:-44.7pt"><strong><u>Distribution:</u></strong></p><p style="margin-right:-44.7pt">Methylprednisolone is widely distributed into the tissues, crosses the blood-brain barrier, and is secreted in breast milk. Its apparent volume of distribution is approximately 1.4 L/kg. The plasma protein binding of methylprednisolone in humans is approximately 77%.</p><p style="margin-right:-44.7pt"><strong><u>Metabolism:</u></strong></p><p style="margin-right:-44.7pt">In humans, methylprednisolone is metabolized in the liver to inactive metabolites; the major ones are 20<strong>&alpha;</strong>-hydroxymethylprednisolone and 20<strong>&beta;</strong>-hydroxymethylprednisolone. Metabolism in the liver occurs primarily via the CYP3A4. (For a list of drug interactions based on CYP3A4-mediated metabolism, see section 4.5 Interactions with Other Medicinal Products and Other Forms of Interaction.) Methylprednisolone, like many CYP3A4 substrates, may also be a substrate for the ATP-binding cassette (ABC) transport protein p-glycoprotein, influencing tissue distribution and interactions with other medicines.</p><p style="margin-right:-44.7pt"><strong><u>Elimination:</u></strong></p><p style="margin-right:-44.7pt">The mean elimination half-life for total methylprednisolone is in the range of 1.8 to 5.2 hours. Total clearance is approximately 5 to 6 mL/min/kg.</p><p style="margin-right:-44.7pt">No dosing adjustments are necessary in renal failure. Methylprednisolone is haemodialysable.</p><p style="margin-right:-44.7pt">Methylprednisolone acetate is less soluble than methylprednisolone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:-44.7pt">Based on conventional studies of safety pharmacology and repeated dose toxicity, no unexpected hazards were identified. The toxicities seen in the repeated-dose studies were those expected to occur with continued exposure to exogenous adrenocortical steroids.</p><p style="margin-right:-44.7pt"><u>Mutagenesis: </u></p><p style="margin-right:-44.7pt">Methylprednisolone has not been formally evaluated for genotoxicity. Studies using structurally related analogues of methylprednisolone showed no evidence of a potential for genetic and chromosome mutations in limited studies in bacteria and mammalian cells.</p><p style="margin-right:-44.7pt"><u>Carcinogenesis:</u></p><p style="margin-right:-44.7pt">Methylprednisolone has not been formally evaluated in rodent carcinogenicity studies. Variable results have been obtained with other glucocorticoids tested for carcinogenicity in mice and rats. However, published data indicate that several related glucocorticoids including budesonide, prednisolone, and triamcinolone acetonide can increase the incidence of hepatocellular adenomas and carcinomas after oral administration in drinking water to male rats. These tumorigenic effects occurred at doses which were less than the typical clinical doses on a mg/m<sup>2</sup> basis. The clinical relevance of these findings is unknown.</p><p style="margin-right:-44.7pt"><u>Reproductive toxicity:</u></p><p style="margin-right:-44.7pt">Methylprednisolone has not been evaluated in animal fertility studies. Corticosteroids have been shown to reduce fertility when administered to rats. Adverse effects on fertility in male rats administered corticosterone were observed and were reversible. Decreased weights and microscopic changes in prostate and seminal vesicles were observed. The numbers of implantations and live foetuses were reduced and these effects were not present following mating at the end of the recovery period.</p><p style="margin-right:-44.7pt">An increased frequency of cleft palate was observed among the offspring of mice treated during pregnancy with methylprednisolone in doses similar to those typically used for oral therapy in humans.</p><p style="margin-right:-44.7pt">An increased frequency of cardiovascular defects and decreased body weight were observed among the offspring of pregnant rats treated with methylprednisolone in a dose that was similar to that used for oral therapy in humans but was toxic to the mothers. In contrast, no teratogenic effect was noted in rats with doses &lt; 1-18 times those typically used for oral therapy in humans in another study. High frequencies of foetal death and a variety of central nervous system and skeletal anomalies were reported in the offspring of pregnant rabbits treated with methylprednisolone in doses less than those used in humans. The relevance of these findings to the risk of malformations in human infants born to mothers treated with methylprednisolone in pregnancy is unknown. Safety margins for the reported teratogenic effects are unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:-44.7pt">Polyethylene glycol, sodium chloride, Benzethonium chloride, sodium hydroxide or hydrochloric acid, water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:-44.7pt">None stated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
Epizolone Depot should not be mixed with any other fluid. Discard any remaining suspension after use.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:-44.7pt">Store at a temperature not exceeding 30 &deg;C.</p><p style="margin-right:-44.7pt">Protect from freezing.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:-44.7pt">Box containing 1 vial 1 ml, or box containing 1 vial 2 ml.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:-25.55pt">No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Egyptian International Pharmaceutical Industries Company, E.I.P.I.CO.
10th of Ramadan City – Industrial Area B1 – P.O. Box: 149 Tenth – Egypt.
Tel: 0554/499199
        0554/499277
Fax: 0554/499306
E-mail: eipico@eipico.com.eg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>